CN114716489A - Targeting ligand and application thereof in therapeutic nucleic acid conjugate - Google Patents

Targeting ligand and application thereof in therapeutic nucleic acid conjugate Download PDF

Info

Publication number
CN114716489A
CN114716489A CN202110008013.3A CN202110008013A CN114716489A CN 114716489 A CN114716489 A CN 114716489A CN 202110008013 A CN202110008013 A CN 202110008013A CN 114716489 A CN114716489 A CN 114716489A
Authority
CN
China
Prior art keywords
integer
dcm
targeting ligand
synthesis
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110008013.3A
Other languages
Chinese (zh)
Inventor
张海霖
刘兆贵
赵维峰
付中国
王正勇
陈璞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Naptide Qingdao Biomedical Co ltd
Original Assignee
Napeptide Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Napeptide Co ltd filed Critical Napeptide Co ltd
Priority to CN202110008013.3A priority Critical patent/CN114716489A/en
Priority to CN202180022902.3A priority patent/CN115516092A/en
Priority to CN202211333934.8A priority patent/CN116333013A/en
Priority to EP21874577.6A priority patent/EP4223875A1/en
Priority to PCT/CN2021/122118 priority patent/WO2022068923A1/en
Priority to JP2022578882A priority patent/JP2023536685A/en
Priority to EP23173354.4A priority patent/EP4331608A1/en
Publication of CN114716489A publication Critical patent/CN114716489A/en
Priority to US18/092,202 priority patent/US20230257750A1/en
Priority to JP2023054421A priority patent/JP2023121159A/en
Priority to US18/130,418 priority patent/US20240067971A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Abstract

The invention belongs to the field of chemistry, and particularly relates to a targeting ligand and application thereof to a therapeutic nucleic acid conjugate. The targeting ligand comprises the following components: n targeting groups, n connecting arms, a branched skeleton and a tail connector. Wherein n is an integer of 1-4, and the number of branches of the branched skeleton is adapted to the number of groups formed by the targeting group and the connecting arm indicated by n. The disclosed targeting ligands can be used to attach therapeutic nucleic acids and target them for delivery to hepatocytes. The conjugate formed by the targeting ligand and the therapeutic nucleic acid (including the expression inhibitory oligomeric compound or RNAi agent) disclosed by the invention can realize effective gene silencing under low dose, and brings good news to patients with serious human diseases, particularly liver target related patients, such as patients with hyperlipidemia and the like.

Description

Targeting ligand and application thereof in therapeutic nucleic acid conjugate
Technical Field
The invention belongs to the field of chemistry, and particularly relates to a targeting ligand and application thereof to a therapeutic nucleic acid conjugate.
Technical Field
The delivery of therapeutic substances, such as small chemical molecules, nucleic acids, polypeptide drugs, etc., to target tissues and organs of a subject is critical to the therapeutic effects of such substances, and substances with diagnostic effects also need to be precisely delivered to target sites of an organism to diagnose diseases, etc. Also, efficient delivery of chemicals/compounds to specific locations may limit or eliminate to some extent the adverse consequences that may result from substance administration, such as its toxic or off-target effects on non-target tissues, organs, etc. To achieve the above object, an effective method is to link a therapeutic substance or the like to a targeting ligand/compound (as a drug carrier) capable of being specifically recognized/bound by a receptor at a target tissue.
Nucleic acids have a wide application prospect as therapeutic agents/drugs, and especially small interfering RNA (siRNA) drugs which are brought along by major breakthroughs in RNA interference (RNAi) technology in recent years inhibit protein expression through gene post-transcriptional silencing, so that the nucleic acids have an important significance for treating human major diseases and genetic diseases. Other small nucleic acid technologies, such as antisense nucleic Acid (ASO), micro rna (mirna), also suppress protein expression by silencing specific genes, to achieve disease treatment. Nucleic acid substances do not have tissue and organ targeting, so a high-efficiency delivery system becomes a core key technology in the development of small nucleic acid drugs, and the most widely researched small nucleic acid delivery system worldwide at present is a liver targeting conjugation delivery technology.
The asialoglycoprotein receptor (ASGP-R) is a transmembrane glycoprotein highly expressed on hepatocytes, and is capable of specifically recognizing galactose (Gal-), N-acetylgalactosamine (GalNAc-), and the like, and has 50-fold higher affinity for GalNAc than for Gal. Mammalian hepatocyte-expressed ASGP-R can achieve drug targeting to the liver by recognizing covalent conjugates of galactose or galactosamine with drugs (P.H.Weigel et al. Biochim.Biophys.acta.2002,1572, 341-363; S.Ishibashi, et al.J.biol.chem.1994,269, 27803-27806). Furthermore, the multivalent effect achieved by repeating the targeting unit can significantly increase the binding affinity (E.A.L.Biessen, et al.J.Med.chem.1995,38,9, 1538-. One of the first disclosures of triantennary clustered glycosides is found in U.S. Pat. No. 5,885,968, and conjugates with three GalNAc ligands and containing phosphate groups are known compounds (Dubber, et al. bioconjugate chem.2003,14(1), 239-. The ASGP-R is very suitable to be used as a recognition and transport medium of a liver cell targeted delivery drug system, the GalNAc ligand-siRNA conjugate can transport siRNA into required tissues and cells through specific recognition and interaction between the ligand and the ASGP-R, and the active targeting strategy can not only reduce the accumulation of siRNA in unexpected tissues so as to reduce or avoid adverse side effects and toxicity, but also realize effective gene silencing at low dose.
Therefore, the invention of a suitable targeting ligand is crucial for constructing a high-efficiency delivery system.
Disclosure of Invention
The invention discovers a novel targeting ligand which can be used for delivering RNAi agents to target cells so as to construct a high-efficiency delivery system. In particular, can be used in liver targeting conjugation delivery technology.
Specifically, the technical scheme of the invention is as follows:
in a first aspect, the present invention discloses a targeting ligand, comprising the structure of formula I:
Figure BDA0002883820160000021
comprising a tail linker, a branched backbone, one or more linker arms, and one or more targeting groups;
wherein n is an integer of 1-4, and the number of branches of the branched skeleton is adapted to the number of groups formed by the targeting group and the connecting arm indicated by n.
Preferably, the targeting group of the targeting ligand is connected with the connecting arm through a glycosidic bond and is independently selected from the group consisting of: galactosyl, 2-amino-galactosyl, 2-acetyl amino galactosyl, 2-formamido-galactosyl, 2-propionamido-galactosyl.
Preferably, the targeting ligand, the targeting group of which is 2-acetamido-galactosyl.
Preferably, the branched skeleton of the targeting ligand is connected to the linker arm through an amino residue, and is connected to the tail linker through a carbonyl residue, and is selected from the following structures:
Figure BDA0002883820160000031
structure a1, wherein x and y are the same or different and are each selected from integers of 1 to 4;
Figure BDA0002883820160000032
structure a2, wherein p and q are the same or different and are each selected from integers of 1 to 4.
Preferably, the targeting ligand has a connecting arm connected to the branched backbone via a carbonyl residue, and is independently selected from the following structures:
Figure BDA0002883820160000033
structure b1, wherein n is an integer from 1 to 3;
Figure BDA0002883820160000034
structure b2, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000035
structure b 3;
Figure BDA0002883820160000036
the structure of the structure b4 is,
Figure BDA0002883820160000037
structure b 5.
Preferably, the branched skeleton of the targeting ligand is connected to the linking arm through a carbonyl residue and connected to the tail linker through an amino residue, and is selected from the following structures:
Figure BDA0002883820160000038
structure a3, wherein m is an integer from 1 to 5;
Figure BDA0002883820160000041
structure a4, wherein x and y are each independently selected from integers of 1-3.
More preferably, the targeting ligand, the linking arm of which is linked to the branched backbone via an amino residue, is independently selected from the following structures:
Figure BDA0002883820160000042
structure b6, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000043
structure b7, wherein n is an integer from 1 to 2 and m is an integer from 1 to 5;
Figure BDA0002883820160000044
structure b8, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000045
structure b9, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000046
structure b10, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000047
structure b11, wherein n is an integer from 1 to 2, and m is an integer from 1 to 5;
Figure BDA0002883820160000048
structure b12, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000049
structure b13, wherein n is an integer from 1 to 2 and m is an integer from 1 to 5;
Figure BDA00028838201600000410
structure b14, wherein n is an integer from 1 to 5;
Figure BDA00028838201600000411
structure b15, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000051
structure b16, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000052
structure b17, wherein n is an integer from 1 to 3.
Preferably, the branched skeleton of the targeting ligand is connected with the connecting arm through a carbonyl residue and connected with the tail linker through an amino residue, and is selected from the following structures:
Figure BDA0002883820160000053
structure a4, wherein x and y are each independently selected from integers of 1-3, and x and y are not 2 at the same time;
Figure BDA0002883820160000054
structure a 5.
Preferably, the linking arm of the targeting ligand is linked to the branched scaffold via an amino residue, and independently has the structure b 18:
preferably, the branched skeleton of the targeting ligand is connected to the linking arm through a carbonyl residue and connected to the tail linker through an amino residue, and has a structure a 6:
Figure BDA0002883820160000055
structure a 6.
Preferably, the linking arm of the targeting ligand is linked to the branched backbone through an amino residue, and is independently selected from the following structures:
Figure BDA0002883820160000061
structure b6, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000062
structure b7, wherein n is an integer from 1 to 2 and m is an integer from 1 to 5;
Figure BDA0002883820160000063
structure b8, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000064
structure b9, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000065
structure b10, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000066
structure b11, wherein n is an integer from 1 to 2, and m is an integer from 1 to 5;
Figure BDA0002883820160000067
structure b12, wherein n is an integer from 1 to 5;
Figure BDA0002883820160000068
structure b13, wherein n is an integer from 1 to 2 and m is an integer from 1 to 5;
Figure BDA0002883820160000069
structure b14, wherein n is an integer from 1 to 5;
Figure BDA00028838201600000610
structure b15, wherein n is an integer from 1 to 5;
Figure BDA00028838201600000611
structure b16, wherein n is an integer from 1 to 5;
Figure BDA00028838201600000612
structure b17, wherein n is an integer from 1 to 3;
Figure BDA0002883820160000071
structure b18, wherein n is an integer from 1 to 3.
Preferably, the targeting ligand, the tail linker of which is linked to the branched backbone via an amino residue, is selected from the following structures:
Figure BDA0002883820160000072
structure c 1;
Figure BDA0002883820160000073
structure c2, wherein n is an integer from 1 to 2.
Preferably, the targeting ligand, the tail linker of which is linked to the branched backbone via a carbonyl residue, is selected from the following structures:
Figure BDA0002883820160000074
structure c 3;
Figure BDA0002883820160000075
structure c 4;
Figure BDA0002883820160000076
structure c 5;
Figure BDA0002883820160000077
structure b1H, wherein n is an integer from 1 to 3;
Figure BDA0002883820160000078
structure b2H, wherein n is an integer from 1 to 2;
Figure BDA0002883820160000079
structure b 3H;
Figure BDA00028838201600000710
the structure b4H is formed by a structure,
Figure BDA00028838201600000711
structure b 5H.
Preferably, the targeting ligand, the linker of which is selected from the group consisting of structures b1H and b2H linked to the branched backbone via a carbonyl residue, and structure c6 via an alkyl residue CH2Connecting with the branch framework:
Figure BDA00028838201600000712
structure b1H, wherein n is an integer from 1 to 3;
Figure BDA00028838201600000713
structure b2H, wherein n is an integer from 1 to 2;
Figure BDA00028838201600000714
structure c6, wherein n is an integer from 0 to 3.
Preferably, the targeting ligand is selected from at least one of the following structures:
Figure BDA0002883820160000081
Figure BDA0002883820160000091
Figure BDA0002883820160000101
Figure BDA0002883820160000111
Figure BDA0002883820160000121
Figure BDA0002883820160000131
Figure BDA0002883820160000141
Figure BDA0002883820160000151
preferably, the targeting ligand described above is linked to a therapeutic nucleic acid. More preferably, the therapeutic nucleic acid is a double-stranded nucleic acid.
In some embodiments of the invention, the therapeutic nucleic acid is an RNAi agent.
The invention discloses a medicament and pharmaceutically acceptable salts thereof in a second aspect, wherein the medicament and the pharmaceutically acceptable salts thereof comprise the targeting ligand.
Preferably, the medicament and pharmaceutically acceptable salts thereof further comprise an RNAi agent; the targeting ligand is connected with the RNAi agent through a chemical group; more preferably, the chemical group is a covalent bond group; in some embodiments of the invention, the targeting ligand is linked to the RNAi agent through a tailpiece terminal residue.
Preferably, the targeting ligand is linked to the RNAi agent through a tail linker terminal oxygen residue to form a phosphate group and/or a phosphorothioate group.
Preferably, the RNAi agent is a therapeutic nucleic acid or an expression-inhibiting oligomer; preferably, the RNAi agent is a double-stranded RNAi agent.
Preferably, the drug and the pharmaceutically acceptable salt thereof comprise at least one selected from the following conjugates:
Figure BDA0002883820160000161
Figure BDA0002883820160000171
Figure BDA0002883820160000181
Figure BDA0002883820160000191
Figure BDA0002883820160000201
Figure BDA0002883820160000211
Figure BDA0002883820160000221
Figure BDA0002883820160000231
wherein R of each conjugate comprises a therapeutic nucleic acid or an expression-inhibiting oligomer.
Preferably, the conjugate is obtained by using the corresponding phosphoramidite compound as a raw material and forming phosphate groups through chemical reaction, connecting/conjugating phosphorothioate groups to therapeutic nucleic acids or expressing inhibitory oligomers;
Figure BDA0002883820160000241
Figure BDA0002883820160000251
Figure BDA0002883820160000261
Figure BDA0002883820160000271
Figure BDA0002883820160000281
Figure BDA0002883820160000291
Figure BDA0002883820160000301
Figure BDA0002883820160000311
preferably, the phosphoramidite compound is contacted with a therapeutic nucleic acid or an expression-inhibiting oligomer having a naked hydroxyl group in the presence of a base, and is chemically reacted to form a phosphate ester or a phosphorothioate group for mutual linkage/conjugation;
more preferably, the therapeutic nucleic acid or expression inhibiting oligomer is single stranded.
Preferably, the phosphoramidite compound is obtained by contacting a phosphoramidite reagent with a corresponding compound as a starting material and then carrying out a phosphoramidite reaction.
Figure BDA0002883820160000321
Figure BDA0002883820160000331
Figure BDA0002883820160000341
Figure BDA0002883820160000351
Figure BDA0002883820160000361
Figure BDA0002883820160000371
Figure BDA0002883820160000381
Figure BDA0002883820160000391
The third aspect of the invention discloses the application of the targeting ligand in the preparation of small nucleic acid drugs.
In a fourth aspect, the present invention discloses a receptor cell, which comprises the targeting ligand.
Preferably, the cell is a mammalian hepatocyte; more preferably, the cell is a human hepatocyte.
The targeting ligands disclosed herein can be chemically linked to a compound, such as a therapeutic compound, e.g., a therapeutic nucleic acid. In some embodiments, the therapeutic nucleic acid is an expression-inhibiting oligomeric compound. In some embodiments, the expression inhibiting oligomeric compound comprises one or more modified nucleotides. In some embodiments, the expression-inhibiting oligomeric compound is an RNAi agent, such as a double-stranded RNAi agent. In some embodiments, a targeting ligand disclosed herein is linked to the 5' end of the sense strand of a double stranded RNAi agent. In some embodiments, a targeting ligand disclosed herein is linked to an RNAi agent at the 5' end of the sense strand of a double stranded RNAi agent via a phosphate or phosphorothioate group.
Disclosed herein are methods or processes for preparing phosphoramidite compounds including a targeting ligand, the methods comprising covalently linking a tail linker to a branched backbone, and contacting the tail linker with a phosphoramidite reagent for acylation to form the phosphoramidite compound.
Disclosed herein are medicaments comprising targeting ligands and methods of making the same.
Notation used herein
Figure BDA0002883820160000401
Meaning that one or more of any chemical groups may be attached within the scope of the present invention.
The term "residue" as used herein denotes an incomplete chemical group or building block, which may pass terminally
Figure BDA0002883820160000402
One or more of any chemical groups are attached.
The term "linked", as used herein, when referring to a linkage between two molecules or groups, means linked by a covalent bond.
The term "oligomeric compound" as used herein refers to a nucleotide sequence containing 10 to 50 nucleotides or nucleotide base pairs. In some embodiments, the oligomeric compound has an antisense strand nucleotide sequence that is at least partially complementary to a target nucleic acid expressed in a cell of the subject. In some embodiments, the expression-inhibiting oligomeric compound is capable of inhibiting expression of a gene after being delivered to a cell expressing the gene, and the inhibiting expression of the gene can be achieved in vitro or in vivo.
Oligomeric compounds include, but are not limited to: oligonucleotides, single stranded antisense oligonucleotides, small interfering RNAs (sirnas), double stranded RNAs (dsrnas), micrornas (mirnas), short hairpin RNAs (shrnas), ribozymes, interfering RNA molecules, and Dicer enzyme substrates.
The term "RNAi agent" as used herein refers to an agent comprising an oligonucleotide capable of inhibiting the translation of a target messenger rna (mrna) in a sequence-specific manner. The RNAi agents used herein may act through an RNA interference mechanism [ i.e., induce RNA interference by interacting with the RNA interference pathway building mechanism (RNA-induced silencing complex or RISC) of mammalian cells ], or by any other mechanism or pathway. Although the term RNAi agent as used herein is believed to act primarily through the mechanism of RNA interference, the disclosed RNAi agents are not limited or restricted to any particular pathway or mechanism of action. RNAi agents include, but are not limited to: oligonucleotides, single stranded antisense oligonucleotides, small interfering RNAs (sirnas), double stranded RNAs (dsrnas), micrornas (mirnas), short hairpin RNAs (shrnas), mrnas, ribozymes, interfering RNA molecules, and Dicer enzyme substrates. RNAi agents described herein include oligonucleotides having a sequence that is at least partially complementary to a target mRNA. In some embodiments, the RNAi agents described herein are double-stranded and include an antisense strand and a sense strand that is at least partially complementary to the antisense strand. RNAi agents can also include chemically modified oligonucleotides.
The term "sequence" as used herein refers to the order or sequence of nucleobases or nucleotides described using a sequence letter of standard nucleotide nomenclature.
The term "nucleic acid conjugate" as used herein refers to a nucleic acid conjugate having a more complex structure formed by covalently linking/conjugating a nucleic acid substance to a molecule including a chemical small molecule, macromolecule, polypeptide, saccharide, lipid, protein, etc.
Unless defined otherwise, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patent applications, patents, and references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification will control. In addition, the materials, methods, and examples recited herein are illustrative only and not intended to be limiting.
In the nucleic acid sequences disclosed herein, the different English letters represent modified nucleotides and linkages, a represents 2 '-O-methyladenosine, u represents 2' -O-methyluridine, G represents 2 '-O-methylguanosine, C represents 2' -O-methylcytosine, Af represents 2 '-fluoroadenosine, Uf represents 2' -fluorouridine, Gf represents 2 '-fluoroguanosine, Cf represents 2' -fluorocytosine, A represents 2 '-deoxyadenosine, T represents 2' -deoxythymidine, G represents 2 '-deoxyguanosine, C represents 2' -deoxycytidine, s represents phosphorothioate linkages, no symbol is present between directly adjacent nucleotides, indicating a normal phosphate linkage.
Compared with the prior art, the invention has at least the following beneficial effects:
the invention discloses a brand-new targeting ligand for a therapeutic conjugate and a phosphoramidite compound thereof, which can be connected with and deliver therapeutic nucleic acid, realize effective gene silencing under low dose and bring gospel to patients with human serious diseases, particularly patients with liver related diseases.
Detailed Description
The present application is further illustrated by the following detailed examples, which should be construed to be merely illustrative and not limitative of the remainder of the disclosure.
The instruments, equipment, reagents used in the examples are available from various sources, for example, purchased, or may be prepared.
The compounds disclosed herein can be prepared using the following synthetic methods.
EXAMPLE 1 Synthesis of Compound TO-1, and phosphoramidite Compound TP-1
This example synthesizes one diastereomer of TO-1 and TP-1 according TO the following procedure.
(1) Synthesis of intermediate GC-2-01
Figure BDA0002883820160000421
In N2Diethylene glycol (40.1g, 0.32mol) was added to dry THF (500mL) under an atmosphere, sodium metal (220mg, 9.6mmol) was added, the solution was stirred at 25 ℃ and tert-butyl acrylate (106.9g, 1.01mol) was slowly added to the reaction. Stirred for 24 h, TLC (petroleum ether/EtOAc: 1/4, R)f0.6) showed the substantial disappearance of the starting material, dilute hydrochloric acid (0.5N,10mL) and concentrated under reduced pressure to give a liquid, purified water (300mL) was added, extracted with EtOAc (200 mL. times.3), and the organic phases were combined and washed with saturated brine (300mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether/EtOAc. 1/1) to give compound GC-2-01(42.3g, 73.2% yield) as a colorless oil. MS (ESI) M/z [ M + NH4]+Theoretical 252.1, found 252.2.
(2) Synthesis of intermediate GC-2-02
Figure BDA0002883820160000422
In N2GC-2-01(42.0g, 179.0mmol) and GN-1-01(73.3g, 188.0mmol) were added to DCM (500mL) under ambient conditions, TMSOTf (19.9g, 89.5mmol) was slowly added dropwise, stirred at 25 ℃ for 16 h, TLC (DCM/MeOH-10/1, R)f0.6) showed substantial disappearance of starting material. Slowly add saturated sodium bicarbonate solution (300mL) to quench, separate, extract with DCM (200 mL. times.2), combine the organic phases and wash with saturated brine (300mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. The crude product was purified by silica gel column chromatography (DCM/MeOH ═ 50/1) to give GC-2-02(53.6g, 53% yield) as a colorless viscous liquid. MS (ESI) M/z [ M + H]+Theoretical 564.3, found 564.3.
(3) Synthesis of intermediate GC-2
Figure BDA0002883820160000431
GC-2-02(15.4g, 27.3mmol) was dissolved in DCM (120mL), TFA (30mL) was added to the reaction, stirred at 25 ℃ for 1h, TLC (DCM/MeOH ═ 10/1, Rf0.2) showed substantial disappearance of starting material. The liquid was concentrated under reduced pressure to give the crude product, which was purified by silica gel column chromatography (DCM/MeOH 40/1) to give GC-2 as a white solid (8.9g, 64.5% yield). MS (ESI) M/z [ M-H]-Theoretical 506.2, found 506.2.
(4) Synthesis of intermediate AN-3-02
Figure BDA0002883820160000432
AN-3-01(3.76g, 7.0mmol) was dissolved in MeCN (100mL), potassium carbonate (1.93g, 14mmol) was added and stirred, BnBr (1.43g, 8.4mmol) was slowly added dropwise to the reaction solution and stirred at 25 ℃ for 12 hours. TLC (petroleum ether/EtOAc: 1/1, R)f0.8) showed substantial disappearance of starting material, MeCN was concentrated under reduced pressure, purified water (100mL) was added, extraction was performed with EtOAc (100mL × 3), organic phases were combined and washed with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. The crude product was purified by silica gel column chromatography (petroleum ether/EtOAc. 3/1) to yield AN-3-02(2.75g, 62.4% yield) as a white solid. MS (ESI) M/z [ M + Na]+Theoretical 631.3, found 631.4.
(5) Synthesis of intermediate AN-3
Figure BDA0002883820160000433
AN-3-02(2.75g, 4.5mmol) and TES (2.62g, 22.5mmol) were dissolved in DCM (40mL), TFA (10mL) was added to the reaction mixture, and stirring was carried out at 25 ℃ for 1 hour, TLC (petroleum ether/EtOAc: 1/1, R)f0.2) showed substantial disappearance of starting material. The liquid was concentrated under reduced pressure, ACN (30 mL. times.2) and purified water (30 mL. times.2) were added to concentrate the residue of TFA, and lyophilized to give Compound AN-3(TFA salt, 3.32g) as a white powdery solid. MS (ESI) M/z [ M + H]+Theoretical value 309.2, found 309.2.
(6) Synthesis of intermediate TO-1-01
Figure BDA0002883820160000441
In N2GC-2(6.09g, 12.0mmol) was dissolved in DCM (150mL) under AN atmosphere, the temperature was lowered to 0-5 ℃ in AN ice bath, HOBt (2.61g, 13.7mmol) and EDCI (1.62g, 12.0mmol) were added, and the mixture was stirred for 10 minutes to obtain AN-3(1.12g, 3.6mmol), DIEA (3.25g,25.2mmol) in DCM (50mL) was slowly added dropwise to the reaction solution, and the reaction was stirred up to 25 ℃ for 16 hours. TLC (DCM/MeOH ═ 10/1, R)f0.6) showed substantial disappearance of starting material. Adding saturated ammonium chloride solution (100mL), quenching, separating, extracting with DCM (100 mL. times.2), combining organic phases, washing with saturated saline (100mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH-10/1) TO give TO-1-01(2.49g, 37.9% yield) as a white solid. MS (ESI) M/z [1/2M + H]+Theoretical 888.9, found 888.8.
(7) Synthesis of intermediate TO-1-02
Figure BDA0002883820160000451
TO a solution of TO-1-01(2.90g, 1.6mmol) in MeOH (30mL) was added 10% Pd/C (600mg), H2Displacement 3 times, stirring 1h at 25 ℃, TLC (DCM/MeOH ═ 10/1, Rf0.4) showed substantial disappearance of starting material, filtered through celite, washing the filter cake with a small amount of MeOH, and concentrated TO give TO-1-02(2.62g, 95% yield) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 1686.7, found 1686.8.
(8) Synthesis of Compound TO-1
Figure BDA0002883820160000452
In N2TO-1-02(1.25g, 0.74mmol) was dissolved in DCM (50mL) under an atmosphere, EDCI (230mg, 1.11mmol), HOBt (129mg, 0.89mmol), DIEA (287mg, 2.22mmol) and trans-p-aminocyclohexanol (107mg, 0.89mmol) were added in sequence with cooling in an ice bath TO 0-5 ℃ and the reaction was stirred at 25 ℃ for 16 hours. TLC (DCM/MeOH ═ 10/1, R)f0.7) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), separated, extracted with DCM (50mL × 2), combined organic phases and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH. RTM. 8/1) TO give white solid TO-1(740 m)g, yield 53%).
1H NMR(400MHz,DMSO-D6)δ8.02(d,J＝7.8Hz,1H),7.96(d,J＝8.3Hz,1H),7.91-7.73(m,5H),7.68(d,J＝7.8Hz,1H),5.18(d,J＝3.2Hz,3H),4.94(dd,J＝11.2,3.2Hz,3H),4.51(d,J＝8.5Hz,3H),4.22-4.11(m,4H),4.05-3.95(m,9H),3.84(dd,J＝19.8,9.0Hz,3H),3.77-3.69(m,3H),3.58-3.50(m,9H),3.49-3.42(m,16H),3.37-3.27(m,1H),3.13-2.83(m,4H),2.42-2.33(m,4H),2.30-2.23(m,2H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.79-1.63(m,15H),1.61-1.47(m,2H),1.22-1.07(m,4H).
MS(ESI):m/z[M+H]+Theoretical 1783.8, found 1784.2; m/z [ M + Na ]]+Theoretical 1805.8, found 1806.1.
(8) Synthesis of Compound TP-1
Figure BDA0002883820160000461
N2TO-1(740mg, 0.41mmol) was dissolved in dry DCM (11mL) under ambient conditions, DIEA (0.35mL, 2.1mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (0.18mL, 0.82mmol) in dry DCM (1mL) was slowly added dropwise with a syringe. The reaction was carried out at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and dilute the organic phase with saturated NaHCO3The solution (10mL) was washed with brine (10mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-1(490mg, 59.5% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.07-7.96(m,2H),7.86-7.71(m,6H),5.18(d,J＝2.9Hz,3H),4.93(dd,J＝11.2,3.0Hz,3H),4.51(d,J＝8.5Hz,3H),4.22-4.11(m,2H),3.99(s,8H),3.84(q,J＝9.0Hz,3H),3.77-3.70(m,3H),3.70-3.59(m,3H),3.58-3.50(m,12H),3.49-3.38(m,20H),3.12-2.84(m,6H),2.72(t,J＝5.9Hz,2H),2.38-2.32(m,4H),2.30-2.23(m,2H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.73(s,11H),1.61-1.48(m,2H),1.39-1.29(m,2H),1.27-1.19(m,2H),1.17-1.13(m,4H),1.09(dd,J＝6.6,2.2Hz,12H)；
31P NMR(162MHz,DMSO-d6)δ145.44；
MS(ESI):m/z[1/2M+H]+Theoretical 992.4, found 992.5.
EXAMPLE 2 Synthesis of TO-2 Compound and TP-2 phosphoramidite Compound
This example synthesizes one diastereomer of TO-2 and TP-2 according TO the following procedure.
(1) Synthesis of intermediate GN-2-01
Figure BDA0002883820160000471
In N2benzyloxycarbonyl-L-alanine (2.05g, 9.2mmol) was dissolved in DCM (100mL) under ambient conditions, cooled to 0-5 ℃ in an ice bath, EDCI (2.01g, 10.5mmol), HoBt (1.24g, 9.2mmol) and DIPEA (4.36mL, 25mmol) were added, stirring was carried out for 10 min, and GN1(3.8g, 8.75mmol) was added to the reaction mixture, the reaction was warmed to 25 ℃ and stirred for 12 h. TLC (Ethyl acetate, R)f0.2) showed that GN-1 had substantially disappeared, quenched by addition of saturated ammonium chloride solution (100mL), separated, extracted with DCM (100mL × 2), the organic phases were combined and washed with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product. The crude product was purified by silica gel column chromatography (DCM/MeOH ═ 20/1) to give GN-2-01(4.43g, yield 79%) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 640.3, found 640.3.
(2) Synthesis of intermediate GN-2
Figure BDA0002883820160000472
To a solution of GN-2-01(4.43g, 7.8mmol) in MeOH (120mL) was added 10% Pd/C (500mg), H2The reaction was stirred under atmosphere for 8 hours. TLC (DCM/MeOH ═ 5/1) showed substantial disappearance of starting material. Filtration through celite and the filter cake rinsed with a small amount of MeOH gave GN-2 as a white solid (3.73g, 95% yield). MS (ESI) M/z [ M + H]+Theoretical 506.2, found 506.3.
(3) Synthesis of intermediate TO-2-01
Figure BDA0002883820160000481
N2AC-1(983mg, 2.4mmol) was dissolved in DCM (100mL) under an atmosphere, the temperature was reduced to 0-5 ℃ in an ice bath, EDCI (1.65g, 8.6mmol), HOBT (1.0g, 7.54mmol), DIEA (3.17mL, 19.2mmol) and GN-2(4.0g, 7.9mmol) were added in this order, the temperature was raised to 25 ℃ and the reaction was stirred for 16 hours, TLC (DCM/MeOH ═ 10/1, Rf0.4) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), separated, extracted with DCM (100mL × 2), combined organic phases and washed with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH ═ 10/1) TO give TO-2-01(3.0g, yield 67%) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 1872.8, found 1873.0.
(4) Synthesis of intermediate TO-2-02
Figure BDA0002883820160000482
TO a solution of TO-2-01(3.0g, 1.6mmol) in MeOH (100mL) was added 10% Pd/C (300mg), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 1 hour. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material. Filtration through celite and the filter cake rinsed with a small amount of MeOH, concentrated TO give the compound TO-2-02(2.7g, 97% yield) as a white foamy solid. MS (ESI) M/z [ M + H]+Theoretical 1738.7, found 1738.8.
(5) Synthesis of Compound TO-2
Figure BDA0002883820160000491
N2Dissolving TO-1-02(1.3g, 0.75mmol) in DCM (50mL) under an atmosphere, cooling TO 0-5 ℃ in an ice bath, and sequentially adding EDCI (215mg, 1.1mmol), HOBt (106mg, 0.79mmol) and DIEA (290mg, 2.25mmol) and cis 4-hydroxycyclohexanecarboxylic acid (129mg, 0.9mmol) were reacted with stirring at 25 ℃ for 16 hours. TLC (DCM/MeOH ═ 10/1, R)f0.3) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), separated, extracted with DCM (50mL × 2), combined organic phases and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH-8/1) TO give TO-1(670mg, 50% yield) as a white solid.
1H NMR(400MHz,DMSO-D6)δ8.43(d,J＝7.3Hz,1H),8.29(d,J＝7.6Hz,1H),8.16(d,J＝7.8Hz,1H),8.12(t,J＝5.5Hz,1H),8.06(t,J＝5.4Hz,1H),8.02(t,J＝5.6Hz,1H),7.97(d,J＝7.7Hz,1H),7.94-7.78(m,4H),5.21(d,J＝3.4Hz,3H),5.02-4.94(m,3H),4.59-4.52(m,3H),4.38-4.21(m,3H),4.18-4.05(m,2H),4.05-4.01(m,10H),3.93-3.83(m,4H),3.82-3.73(m,4H),3.62-3.55(m,4H),3.54-3.45(m,4H),3.43-3.36(m,6H),3.30-3.10(m,6H),2.21-2.08(m,14H),1.99(s,9H),1.89(s,9H),1.83-1.76(m,11H),1.76-1.68(m,4H),1.66-1.58(m,2H),1.44-1.33(m,4H),1.22(d,J＝7.2Hz,3H),1.19(d,J＝7.1Hz,3H),1.19(d,J＝7.1Hz,3H).
MS(ESI):m/z[M+Na]+Theoretical 1886.8, found 1887.2.
(6) Synthesis of Compound TP-2
Figure BDA0002883820160000501
N2TO-2(500mg, 0.268mmol) was dissolved in dry DCM (7.5mL) under an atmosphere, DIEA (0.22mL, 1.34mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (0.12mL, 0.54mmol) in dry DCM (1mL) was slowly added dropwise via syringe and reacted at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and dilute the organic phase with saturated NaHCO3(10mL) solution, washed with saturated brine (10mL), anhydrous MgSO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-2(410mg,yield 74%).
EXAMPLE 3 Synthesis of Compound TO-3, and phosphoramidite Compound TP-3
This example synthesizes one diastereomer of TO-3 and TP-3 according TO the following procedure.
(1) Synthesis of intermediate NC-1-02
Figure BDA0002883820160000502
Compound NC-1-01(6g, 19.9mmol) was dissolved in DCM (150mL), 50% NaOH solution (50mL), TBAB (0.96g, 2.9mmol), and t-butyl bromoacetate (27.2g, 139.3mmol) were added, and the mixture was allowed to react at 45 ℃ for 24 hours. Mass spectrometry showed the formation of the desired product, concentration, dilution with water (100mL), extraction with petroleum ether (100 mL. times.3), and combined organic phases washed with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. The crude product was purified by column chromatography (petroleum ether/EtOAc. 5/1) to yield NC-1-02 as a yellow oil (8.2g, 64% yield). MS (ESI) M/z [ M + H]+Theoretical 644.4, found 644.5.
(2) Synthesis of intermediate NC-1
Figure BDA0002883820160000511
NC-1-02(8.2g, 12.7mmol) was dissolved in DCM/TFA (100mL/50mL), stirred at 25 ℃ for 5 hours and the starting material essentially disappeared by mass spectrometry. The reaction was concentrated, excess TFA was removed by azeotropy of MeCN (50 mL. times.3) with TFA and dried in vacuo to give NC-1(6.03g) as a colorless oil. MS (ESI) M/z [ M + H]+Theoretical 476.2, found 476.2.
(3) Synthesis of intermediate TO-3-01
Figure BDA0002883820160000512
N2Under an atmosphere, the starting material NC-1(900mg, 1.89mmol) was dissolved in a mixed solvent of DCM (20mL) and DMF (2mL)The temperature is reduced to 0-5 ℃ in ice bath, TBTU (2g, 6.2mmol) and DIEA (1.88mL, 11.4mmol) are added for reaction for 10 minutes, then GN-2(3.16g, 6.26mmol) is added, and the temperature is raised to 25 ℃ for reaction for 16 hours. TLC (DCM/MeOH-10/1, Rf0.4) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), extracted with DCM (50mL × 3), combined organic phases and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH ═ 10/1) TO give TO-3-01(1.73g, 47% yield) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 1937.8, found 1937.7.
(4) Synthesis of intermediate TO-3-02
Figure BDA0002883820160000521
TO a solution of TO-3-01(1.73g, 0.89mmol) in MeOH (30mL) was added 10% Pd/C (346mg), dilute hydrochloric acid (2N, 0.1mL), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 6 hours. TLC (DCM/MeOH — 10/1) showed substantial disappearance of starting material. Filtration through celite and the filter cake rinsed with a small amount of MeOH gave white solid TO-3-02(1.57g, 99% yield). MS (ESI) M/z [ M + H]+Theoretical 1757.7, found 1757.6.
(5) Synthesis of intermediate TO-3-03
Figure BDA0002883820160000522
N2L-1(152mg, 0.68mmol) was dissolved in DCM (20mL) and DMF (2mL) under an atmosphere, HATU (285mg, 0.75mmol) and DIEA (0.17mL, 1.0mmol) were added, the temperature was lowered TO 0-5 ℃ in an ice bath, and stirring was carried out for 10 minutes, followed by TO-3-02(1.2g, 0.68mmol) and rising TO 25 ℃ and stirring was carried out for 12 hours. TLC (DCM/MeOH ═ 8/1, R)f0.3) showed substantial disappearance of starting material. Quenched by addition of saturated ammonium chloride solution (50mL), extracted with DCM (50 mL. times.3), the organic phases combined and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. The crude product is purified by chromatography on a silica gel column (DCM-MeOH ═ 10/1) gave white solid TO-3-03(1.1g, 53% yield). MS (ESI) M/z [ M + H]+Theoretical 1963.8, found 1963.8.
(6) Synthesis of Compound TO-3
Figure BDA0002883820160000531
TO a solution of TO-3-03(1.1g, 0.56mmol) in MeOH (20mL) was added 10% Pd/C (220mg), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 2 hours. TLC (DCM/MeOH-8/1, Rf0.2) showed substantial disappearance of starting material. The crude product was obtained by filtration through celite, rinsing the filter cake with a small amount of MeOH and concentration. The crude product was purified by silica gel column chromatography (DCM/MeOH/TEA-10/1/0.1) TO give TO-3(730mg, yield 77%) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.98(t,J＝5.2Hz,3H),7.89(s,1H),7.79(d,J＝9.2Hz,3H),7.70(d,J＝7.6Hz,3H),5.18(d,J＝3.1Hz,3H),4.94(dd,J＝11.2,3.3Hz,3H),4.51(d,J＝8.5Hz,3H),4.29(m,5H),3.99(s,10H),3.93-3.77(m,10H),3.80-3.66(m,9H),3.57-3.52(m,5H),3.48-3.45(m,4H),3.44-3.41(m,3H),3.39-3.31(m,8H),3.24-3.10(m,6H),2.36(t,J＝6.3Hz,2H),2.07(s,9H),1.96(s,9H),1.86(s,9H),1.74(s,9H),1.18(d,J＝6.9Hz,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 937.4, found 937.7.
EXAMPLE 4 Synthesis of Compound TO-4, and phosphoramidite Compound TP-4
This example synthesizes one diastereomer of TO-4 and TP-4 according TO the following procedure.
(1) Synthesis of intermediate GC-1-02
Figure BDA0002883820160000532
N2GN-1-01(30.7g, 78.86mmol) and GC-1-01(15g, 78.86mmol) were mixed in DCM (500mL) under an atmosphere, TMSOTf (8.7g, 39.4mmol) was added dropwise, and the reaction was carried out at 25 ℃ for 16 hours. TLC detection, the starting material basically disappears, and saturated carbon is addedQuench with sodium hydrogen carbonate solution (50mL), separate the layers, wash the organic phase with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated to obtain GC-1-02(35g) as a white solid which was used in the next step without purification. MS (ESI) M/z [ M + H]+Theoretical 520.2, found 520.2.
(2) Synthesis of intermediate GC-1
Figure BDA0002883820160000541
Dissolving GC-1-02 crude product (35g, 67.3mmol) in DCM/TFA (300mL/150mL), reacting at 25 deg.C for 2 hours, detecting by TLC that the starting material has substantially disappeared, concentrating the solvent to obtain crude product, adding saturated sodium bicarbonate solution to adjust pH to 9, extracting with DCM (200 mL. times.2), adjusting the pH of the aqueous phase to 2 with 2N dilute hydrochloric acid, extracting with DCM (300 mL. times.5), combining the organic phases, adding anhydrous Na2SO4Dried, filtered and concentrated to obtain white solid GC-1(18g, two step yield 50%).
(3) Synthesis of intermediate AN-1-01
Figure BDA0002883820160000542
Reacting (2S) -2, 5-bis [ (tert-butyloxycarbonyl) amino group]Dissolving valeric acid (7.3g, 31.5mmol) and NMM (9g, 90.2mmol) in THF (150mL), cooling to 0-5 deg.C in ice bath, slowly adding isobutyl chloroformate (4.3g, 31.5mmol) dropwise, stirring for 1 hr, adding tert-butoxycarbonyl-L-ornithine (10g, 30mmol), heating to 25 deg.C, reacting for 3 hr, detecting the target product by mass spectrometry, adding 1N hydrochloric acid to the reaction solution, neutralizing, separating, extracting the aqueous phase with EtOAc (100mL × 3), combining the organic phases, washing with saturated saline (100mL), and adding anhydrous Na2SO4Dried, filtered and concentrated to give AN-1-01(10g) as a white solid which was used in the next step without purification.
(4) Synthesis of intermediate AN-1-02
Figure BDA0002883820160000543
Dissolving crude AN-1-01(5.2g, 9.5mmol) in ACN (300mL), adding anhydrous potassium carbonate (3.9g, 28.5mmol), stirring, cooling to 0-5 ℃ in AN ice bath, dropwise adding benzyl bromide (1.95g, 11.4mmol), and stirring at 25 ℃ for 16 hours. TLC showed the starting material had substantially disappeared, filtered and the filtrate was concentrated to give crude product which was purified by silica gel column chromatography (petroleum ether/EtOAc: 2/1) to give AN white solid AN-1-02(4g, 66.7% yield).
(5) Synthesis of intermediate AN-1
Figure BDA0002883820160000551
AN-1-02(4g, 6.28mmol) was dissolved in DCM/TFA (200mL/100mL), stirred at 25 ℃ for 3h, checked by TLC, starting material was substantially disappeared, solvent was concentrated, acetonitrile (100 mL. times.3) was added to azeotropically remove TFA, and after drying in vacuo AN-1(TFA salt, 3.9g) was obtained as a pale yellow oil which was used directly in the next reaction.
(6) Synthesis of intermediate TO-4-01
Figure BDA0002883820160000552
N2Under the atmosphere, dissolving GC-1(7.3g, 15.78mmol) in DCM (100mL), cooling to 0-5 ℃ in ice bath, adding EDCI (3.4g, 17.69mmol) and HOBt (2.1g, 15.78mmol), stirring for 10 minutes, then adding AN-1(3g, 4.78mmol) and DIEA (4.9g, 38.3mmol), raising to 25 ℃, reacting for 5 hours, detecting by TLC, basically eliminating raw materials, adding saturated ammonium chloride solution (50mL), quenching, separating, adding DCM (100mL multiplied by 2) for extraction, combining organic phases, washing with saturated saline (100mL), and anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH-10/1) TO give TO-4-01(5g, yield 62.5%) as a white solid.
(7) Synthesis of intermediate TO-4-02
Figure BDA0002883820160000561
TO a solution of TO-4-01(5g, 2.99mmol) in MeOH (100mL) was added 10% Pd/C (300mg), H2The mixture was stirred at 25 ℃ for 1 hour under ambient conditions, TLC checked, starting material was substantially lost, filtered through celite, the filter cake rinsed with a small amount of MeOH, and concentrated TO give crude TO-4-02(4.4g, 93.6% yield) as a white solid.
(8) Synthesis of Compound TO-4
Figure BDA0002883820160000562
N2Dissolving TO-4-02(2g, 1.26mmol) in DCM (100mL) under an atmosphere, cooling TO 0-5 ℃ in an ice bath, adding EDCI (363mg, 1.89mmol), HOBt (205mg, 0.79mmol), DIEA (488mg, 3.78mmol) and diglycolamine (160mg, 1.52mmol) in sequence, heating TO 25 ℃, reacting for 5 hours, detecting by TLC, basically eliminating the raw materials, adding saturated ammonium chloride solution (50mL) TO quench, separating, adding DCM (100mL multiplied by 2) TO extract, combining organic phases, washing with saturated saline solution (100mL), and adding anhydrous Na2SO4Dried, filtered and concentrated. The crude product was purified by silica gel column chromatography (DCM/MeOH-10/1) TO give TO-4(1g, 50% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.07-7.57(m,8H),5.21(d,J＝3.3Hz,3H),4.96(dt,J＝11.3,3.8Hz,3H),4.54(dd,J＝8.5,2.3Hz,3H),4.27-4.15(m,3H),4.04-4.00(m,7H),3.92-3.83(m,4H),3.77-3.71(m,4H),3.61-3.55(m,9H),3.52-3.42(m,8H),3.41-3.37(m,4H),3.24-3.17(m,2H),3.07-2.96(m,4H),2.43-2.34(m,4H),2.32-2.25(m,2H),2.10(s,9H),1.99(s,9H),1.89(s,9H),1.78(s,9H),1.85-1.47(m,2H),1.47-1.28(m,6H).
MS(ESI):m/z[M+H]+Theoretical 1669.7, found 1670.2; m/z [ M + Na ]]+Theoretical 1691.7, found 1692.1.
EXAMPLE 5 Synthesis of Compound TO-5, and phosphoramidite Compound TP-5
This example synthesizes one diastereomer of TO-5 and TP-5 according TO the following procedure.
(1) Synthesis of intermediate AN-2-02
Figure BDA0002883820160000571
Compound AN-2-01(5g, 9.2mmol) was added to a mixed solution of diethylamine/acetonitrile (50mL, v/v-1/4), and stirred at 25 ℃ for 1 hour. TLC (EtOAc, R)f0.15) showed the starting material had essentially disappeared and was concentrated to give crude product which was purified by silica gel column chromatography (EtOAc) to give AN n-2-02 as light yellow oil (2.66g, 89.7% yield).
(2) Synthesis of intermediate AN-2-03
Figure BDA0002883820160000572
N2Under the atmosphere, (2S) -2, 5-bis [ (tert-butyloxycarbonyl) amino group]Pentanoic acid (1.96g, 5.9mmol) was dissolved in DCM (30mL) and stirred, and EDCI (1.25g,6.5mmol), HOBt (838mg, 6.2mmol), DIEA (2.4mL, 14.75mmol), AN-2-02(2.0g, 6.2mmol) and AN-2-02(2.0g, 6.2mmol) were added in this order and reacted at 25 ℃ for 16 hours. TLC detection shows that the carboxylic acid is basically disappeared, water (20mL) is added for quenching, liquid separation is carried out, an organic phase is washed by saturated saline solution (20mL), dried by anhydrous sodium sulfate, filtered and concentrated to obtain a crude product. Purification by column chromatography (DCM/MeOH-40/1) gave AN-2-03 as a white solid (3.1g, 82% yield).
(3) Synthesis of intermediate AN-2
Figure BDA0002883820160000573
AN-2-03(1.8g, 2.83mmol) was dissolved in TFA/DCM (6mL/12mL) and reacted at 25 ℃ for 1 h. TLC detection of essentially no starting material, concentration, azeotropic removal of excess TFA with acetonitrile (30 mL. times.5) and TFA and drying in vacuo afforded AN-2(TFA salt, 1.77g) as a yellow viscous material which was used in the next step without purification.
(4) Synthesis of intermediate TO-5-01
Figure BDA0002883820160000581
N2GC-1(4.07g, 8.77mmol) was dissolved in DCM (40mL) under AN atmosphere, the temperature was lowered to 0-5 ℃ in AN ice bath, EDCI (1.71g, 8.91mmol), HOBt (1.19g, 8.77mmol) and DIEA (3.3mL, 19.8mmol) were added in this order, the mixture was stirred for 10 minutes, and a solution of AN-2(1.77g,2.83mmol) in DCM (20mL) was added dropwise to the reaction mixture, the mixture was warmed to 25 ℃ and reacted for 16 hours. The reaction was diluted with DCM (50mL), washed with dilute hydrochloric acid (1N, 30mL), the hydrochloric acid phase was extracted with DCM (100mL), the organic phases were combined, washed with saturated sodium bicarbonate solution (50mL), saturated brine (50mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-5-01(2.35g, 49.7% yield) as a white solid.
(5) Synthesis of intermediate TO-5-02
Figure BDA0002883820160000582
TO a solution of TO-5-01(2.15g,1.29mmol) in MeOH (30mL) was added 10% Pd/C (500mg), and the mixture was replaced with hydrogen 3 times and reacted at 25 ℃ for 1 hour. TLC detection, substantial disappearance of starting material, filtration, washing of the filter cake with MeOH (10mL), and concentration of the filtrate afforded TO-5-02 as a white solid (2.0g, 98% yield).
(6) Synthesis of Compound TO-5
Figure BDA0002883820160000591
N2TO-5-02(1g, 0.63mmol) was dissolved in DCM (20mL) under an atmosphere, the temperature was lowered TO 0-5 ℃ in an ice bath, EDCI (133mg, 0.7mmol), HOBt (95mg, 0.7mmol) and DIEA (0.26mL, 1.58mmol) were sequentially added thereto, the mixture was stirred for 10 minutes, diglycolamine (79mg,0.76mmol) was added TO the reaction mixture, and the reaction was carried out at 25 ℃ for 16 hours. TLC detection, essential disappearance of starting material, addition of saturated ammonium chloride solution (20mL), quenching, extraction with DCM (30 mL. times.3), combination of organic phases and washing with saturated brine (50mL), anhydrous Na2SO4Drying the mixtureFiltering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-5(600mg, 57% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.12-8.03(m,1H),8.00-7.70(m,7H),5.18(d,J＝3.3Hz,3H),4.93(dt,J＝11.3,3.7Hz,3H),4.50(d,J＝8.5Hz,3H),4.27-4.12(m,4H),4.04-3.94(m,9H),3.84(dd,J＝19.8,9.0Hz,4H),3.76-3.67(m,4H),3.59-3.49(m,9H),3.47-3.42(m,6H),3.40-3.34(m,5H),3.22-3.10(m,2H),3.06-2.94(m,4H),2.42-2.20(m,6H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.75(s,9H),1.67-1.23(m,6H).
MS(ESI):m/z[M+H]+Theoretical 1669.7, found 1670.2; m/z [ M + Na ]]+Theoretical 1691.7, found 1692.2.
EXAMPLE 6 Synthesis of Compound TO-6, and phosphoramidite Compound TP-6
This example synthesizes one diastereomer of TO-6 and TP-6 according TO the following procedure.
(1) Synthesis of Compound TO-6
Figure BDA0002883820160000601
In N2TO-1-02(1.37g, 0.82mmol) was dissolved in DCM (50mL) under an atmosphere, the temperature was lowered TO 0-5 ℃ in an ice bath, EDCI (233mg, 1.22mmol), HOBt (121mg, 0.89mmol) and DIEA (315mg, 2.44mmol) were sequentially added, stirring was carried out for 10 minutes, diglycolamine (104mg, 0.99mmol) was added TO the reaction mixture, and the reaction mixture was stirred at 25 ℃ for 16 hours. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), separated, extracted with DCM (50mL × 2), combined organic phases and washed with saturated sodium bicarbonate solution (50mL), saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-8/1) gave TO-6(600mg, 41.6% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.12-8.05(m,2H),7.99-7.94(m,1H),7.92-7.86(m,1H),7.83(d,J＝8.8Hz,4H),5.21(d,J＝3.4Hz,3H),4.97(dd,J＝11.2,3.4Hz,3H),4.59(t,J＝5.4Hz,1H),4.54(d,J＝8.5Hz,3H),4.30-4.15(m,2H),4.03(s,9H),3.87(dt,J＝11.1,8.9Hz,3H),3.81-3.73(m,3H),3.61-3.54(m,10H),3.52-3.44(m,21H),3.42-3.37(m,5H),3.27-3.17(m,2H),3.14-2.90(m,4H),2.43-2.35(m,4H),2.29(t,J＝6.5Hz,2H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.77-1.69(m,11H),1.64-1.53(m,2H).
MS(ESI):m/z[M+Na]+Theoretical 1794.8, found 1795.1.
EXAMPLE 7 Synthesis of Compound TO-7, and phosphoramidite Compound TP-7
This example synthesizes one diastereomer of TO-7 and TP-7 according TO the following procedure.
(1) Synthesis of intermediate AN-4-01
Figure BDA0002883820160000602
Dissolving N-fluorenylmethoxycarbonyl-N' -tert-butyloxycarbonyl-L-2, 4-diaminobutyric acid (13.2g, 30mmol) in ACN (300mL), adding potassium carbonate (12.3g, 90mmol), then dropwise adding benzyl bromide (5.6g, 33mmol), stirring at 25 ℃ for 16 hours for reaction, detecting by TLC, basically eliminating the raw materials, filtering, washing a filter cake with a small amount of ACN, and concentrating the filtrate to obtain a crude product. Pulping the crude product with petroleum ether (300mL) for 1 hr, vacuum filtering, collecting filter cake, and oven drying to obtain white solid AN-4-01(13g, yield 86%).
(2) Synthesis of intermediate AN-4-02
Figure BDA0002883820160000611
Dissolving AN-4-01(13g, 24.4mmol) in ACN/diethylamine (120mL/30mL), stirring at 25 deg.C for 16 hr, detecting by TLC, removing raw material, and concentrating the filtrate to obtain crude product. Purification by column chromatography (EtOAc) afforded AN-4-02 as a pale yellow oil (7g, 93% yield).
(3) Synthesis of intermediate AN-4-03
Figure BDA0002883820160000612
Dissolving AN-3-01(3.75g, 1.79mmol) and NMM (3.5g, 35.4mmol) in THF (50mL), cooling to 0-5 ℃ in ice bath, slowly adding isobutyl chloroformate (1.9g, 14.2mmol) dropwise, stirring for 1 hour, adding AN-4-02(4g, 13mmol), heating to 25 ℃ for reaction for 3 hours, detecting the target product by mass spectrometry, adding 1N hydrochloric acid to the reaction solution for neutralization, separating liquid, extracting the aqueous phase with EtOAc (50mL × 3), combining the organic phases, washing with saturated saline (100mL), and adding anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-40/1) gave AN-4-03 as a white solid (7.5g, 75% yield).
(4) Synthesis of intermediate AN-4
Figure BDA0002883820160000613
AN-4-03(5.3g, 8.7mmol) was dissolved in DCM/TFA (60mL/30mL) and reacted at 25 ℃ for 1 hour. TLC detection, starting material had essentially disappeared, concentrated, and the excess TFA was removed azeotropically with acetonitrile (30 mL. times.5) and TFA and dried in vacuo to give AN-4(TFA salt, 5.2g) which was used in the next step without purification.
(5) Synthesis of intermediate TO-7-01
Figure BDA0002883820160000621
N2GC-2(3.5g, 6.89mmol) was dissolved in DCM (100mL) under AN atmosphere, the temperature was lowered to 0-5 ℃ in AN ice bath, EDCI (1.4g, 7.29mmol), HOBt (877mg, 6.5mmol) and DIEA (1mL, 6.5mmol) were added in this order, the mixture was stirred for 10 minutes, AN-4(607mg, 1.97mmol) was added to the reaction mixture, and the reaction mixture was reacted at 25 ℃ for 16 hours. TLC detection, essential disappearance of starting material, quenching with saturated ammonium chloride solution (50mL), extraction with DCM (100 mL. times.2), combining the organic phases and washing with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-7-01(1.5g, 43% yield) as a white solid.
(6) Synthesis of intermediate TO-7-02
Figure BDA0002883820160000622
TO a solution of TO-7-01(1.5g, 8.4mmol) in MeOH (30mL) was added 10% Pd/C (300mg), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 1 hour. TLC detection, essential disappearance of starting material, filtration, washing of the filter cake with MeOH (10mL), and concentration of the filtrate TO give white solid TO-7-02(1.3g, 92.8% yield).
(7) Synthesis of Compound TO-7
Figure BDA0002883820160000631
In N2TO-7-02(1.3g, 0.77mmol) was dissolved in DCM (50mL) under an atmosphere, the temperature was lowered TO 0-5 ℃ in an ice bath, EDCI (222mg, 1.2mmol), HOBt (124mg, 0.92mmol) and DIEA (0.38mL, 2.31mmol) were sequentially added and stirred for 10 minutes, diglycolamine (97mg, 0.92mmol) was added TO the reaction mixture, and the reaction mixture was stirred for 16 hours while the temperature was raised TO 25 ℃. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (50mL), separated, extracted with DCM (50mL × 2), combined organic phases and washed with saturated sodium bicarbonate solution (50mL), saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-8/1) gave TO-7(900mg, 69% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.17-7.95(m,2H),7.93(m,1H),7.83-7.72(m,5H),5.18(d,J＝3.4Hz,3H),4.94(dd,J＝11.2,3.4Hz,3H),4.51(d,J＝8.5Hz,3H),4.26-4.14(m,2H),4.04-3.95(m,9H),3.84(dt,J＝11.2,8.9Hz,3H),3.78-3.69(m,3H),3.58-3.50(m,10H),3.49-3.40(m,20H),3.39-3.34(m,4H),3.27-2.90(m,6H),2.42-2.31(m,2H),2.28-2.23(m,4H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.73(s,11H),1.65-1.51(m,2H).
MS(ESI):m/z[M+H]+Theoretical 1773.8, found 1774.1.
EXAMPLE 8 Synthesis of Compound TO-8, and phosphoramidite Compound TP-8
This example synthesizes one diastereomer of TO-8 and TP-8 according TO the following procedure.
(1) Synthesis of intermediate AN-5
Figure BDA0002883820160000641
AN-5-01(220mg, 0.33mmol) was dissolved in TFA/DCM (1.5mL/3mL) and the reaction was stirred at 25 ℃ for 1 h. TLC detection, starting material had essentially disappeared, concentrated, and excess TFA was removed azeotropically with acetonitrile (20 mL. times.5) and TFA and dried in vacuo to give AN-5(TFA salt, 216mg) which was used in the next step without purification.
(2) Synthesis of intermediate TO-8-01
Figure BDA0002883820160000642
N2GC-2(507mg,1mmol) was dissolved in DCM (10mL) under AN atmosphere, cooled to 0-5 ℃ in AN ice bath, EDCI (199mg,1.04mmol), HOBt (135mg, 1mmol) and DIEA (0.26mL, 1.58mmol) were added in sequence, stirred for 10 min, AN-5(227mg, 0.33mmol) was added, and the reaction was stirred at 25 ℃ for 16 h. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (10mL), separated, extracted with DCM (20mL × 2), combined organic phases and washed with saturated brine (20mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-10/1) gave TO-8-01(460mg, 76% yield) as a white solid.
(3) Synthesis of intermediate TO-8-02
Figure BDA0002883820160000651
TO a solution of TO-8-01(460mg, 0.25mmol) in MeOH (10mL) was added 10% Pd/C (130mg), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 1 hour. TLC detection, substantial disappearance of starting material, filtration, MeOH (10mL)) The filter cake was washed and the filtrate was concentrated TO give TO-8-02(435mg, yield 100%) as a white solid.
(3) Synthesis of Compound TO-8
Figure BDA0002883820160000652
N2TO-8-02(435mg, 0.25mmol) was dissolved in DCM (10mL) under an atmosphere, cooled TO 0-5 ℃ in an ice bath, EDCI (53mg, 0.28mmol), HOBt (35mg,0.26mmol) and DIEA (0.1mL,0.63mmol) were added in sequence, stirred for 10 min, diglycolamine (32mg, 0.3mmol) was added, and the reaction was stirred at 25 ℃ for 16 h. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (10mL), separated, extracted with DCM (20mL × 2), combined organic phases and washed with saturated brine (20mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-8/1) gave TO-8(300mg, 65.6% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.95(d,J＝7.4Hz,1H),7.83(t,J＝5.0Hz,1H),7.80-7.72(m,5H),5.18(d,J＝3.2Hz,3H),4.94(dd,J＝11.1,3.3Hz,3H),4.51(d,J＝8.5Hz,3H),4.21-4.08(m,3H),3.99(br s,9H),3.89-3.80(m,3H),3.77-3.71(m,3H),3.58-3.50(m,10H),3.48-3.39(t,J＝7.4Hz,20H),3.38-3.34(m,3H),3.25-3.07(m,2H),3.01-2.92(m,4H),2.41-2.31(m,2H),2.29-2.23(m,4H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.74(s,9H),1.64-1.51(m,2H),1.51-1.38(m,2H),1.37-1.27(m,4H),1.26-1.09(m,4H).
MS(ESI):m/z[M+H]+Theoretical 1829.8, found 1830.2; m/z [ M + Na ]]+Theoretical 1851.8, found 1852.1.
Example 9 Synthesis of Compound TO-9, and phosphoramidite Compound TP-9
This example synthesizes one diastereomer of TO-9 and TP-9 according TO the following procedure.
(1) Synthesis of Compound TO-9
Figure BDA0002883820160000661
N2TO-4-02(2g, 1.26mmol) was dissolved in DCM (50mL) under an atmosphere, cooled TO 0-5 ℃ in ice bath, EDCI (363mg, 1.89mmol), HOBt (205mg, 0.79mmol) and DIEA (0.63mL, 3.78mmol) were added sequentially, stirred for 10 min, followed by addition of trans 4-aminocyclohexanol (175mg, 1.52mmol), heating TO 25 ℃ and stirring for reaction for 16 h. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (30mL), separated, extracted with DCM (50mL × 2), combined organic phases and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-10/1) gave TO-9(1.3g, 61% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.00-7.76(m,8H),7.69(m,1H),5.21(d,J＝3.4Hz,3H),4.96(m,3H),4.54(d,J＝8.5Hz,3H),4.20(m,2H),4.02(m,9H),3.88(m,3H),3.78-3.72(m,3H),3.62-3.52(m,9H),3.53-3.43(m,7H),3.38-3.30(m,1H),3.05-2.95(m,4H),2.42-2.28(m,6H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.78(s,11H),1.73-1.66(m,2H),1.63-1.50(m,2H),1.48-1.27(m,6H),1.23-1.12(m,4H).
MS(ESI):m/z[M+Na]+Theoretical 1701.7, found 1702.2.
EXAMPLE 10 Synthesis of Compound TO-10, and phosphoramidite Compound TP-10
This example synthesizes one diastereomer of TO-10 and TP-10 according TO the following procedure.
(1) Synthesis of Compound TO-10
Figure BDA0002883820160000671
N2TO-5-02(1g, 0.73mmol) was dissolved in DCM (20mL) under an atmosphere, cooled TO 0-5 ℃ in an ice bath, EDCI (154mg, 0.8mmol), HOBt (103mg, 0.76mmol) and DIEA (0.3mL, 1.83mmol) were added in this order, stirred for 10 min, followed by addition of trans 4-aminocyclohexanol (100mg, 0.87mmol), heating TO 25 ℃ and stirring for 16 h. TLC (DCM/MeOH. RTM. 10/1) showed substantial disappearance of starting material, addQuenched with saturated ammonium chloride solution (20mL), separated, extracted with DCM (30 mL. times.2), the organic phases combined and washed with saturated brine (30mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-10/1) gave TO-10(800mg, 65% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.13-7.95(m,2H),8.02-7.94(m,1H),7.87-7.72(m,5H),7.63-7.51(m,1H),5.18(d,J＝3.4Hz,3H),4.98-4.85(m,3H),4.50(d,J＝8.5Hz,3H),4.23-4.05(m,3H),4.03-3.93(m,8H),3.89-3.80(m,4H),3.75-3.68(m,4H),3.59-3.49(m,9H),3.47-3.37(m,6H),3.35-3.26(m,1H),3.0-2.92(m,4H),2.40-2.23(m,6H),2.07(s,9H),1.96(s,9H),1.85(s,9H),1.75(s,11H),1.70-1.48(m,4H),1.45-1.23(m,6H),1.20-1.06(m,4H).
MS(ESI):m/z[M+Na]+Theoretical value 1701.7, found value 1702.1.
(2) Synthesis of Compound TP-10
Figure BDA0002883820160000681
N2TO-10(610mg, 0.36mmol) was dissolved in dry DCM (9mL) under an atmosphere, DIEA (0.3mL, 1.8mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylchlorophosphimidamide (0.16mL, 0.72mmol) in dry DCM (1mL) was added slowly dropwise with syringe. The reaction was carried out at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and use saturated NaHCO for the organic phase3The solution (10mL) was washed with brine (10mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-10(430mg, 63% yield) as a white solid.
31P NMR(162MHz,DMSO-d6)δ145.43；
MS(ESI):m/z[1/2M+H]+Theoretical 940.4, found 940.2.
EXAMPLE 11 Synthesis of Compound TO-11, and phosphoramidite Compound TP-11
This example synthesizes one diastereomer of TO-11 and TP-11 according TO the following procedure.
(1) Synthesis of intermediate L-1-01
Figure BDA0002883820160000682
2-Benzyloxyethanol (10.10g, 66.4mmol) and tert-butyl acrylate (42.89g, 331.8mmol) were dissolved in DCM (200mL), tetrabutylammonium bromide (4.20g, 13.3mmol) and a 5N NaOH solution (13.22g, 331.8mmol) were added, and the mixture was stirred at 25 ℃ for 16 hours. TLC (petroleum ether/EtOAc: 5/1, R)f0.7) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (100mL), separated, extracted with DCM (100mL × 2), combined organic phases and washed with saturated brine (150mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (petroleum ether/EtOAc: 15/1) gave L-1-01(16.5g, 88.7% yield) as a white solid. MS (ESI) M/z [ M + NH4]+Theoretical 298.2, found 298.3.
(2) Synthesis of intermediate L-1
Figure BDA0002883820160000691
L-1-01(16.5g, 32.6mmol) was dissolved in TFA/DCM (60mL/120mL) and the reaction was stirred at 25 ℃ for 1 h. TLC detection gave essentially no starting material, which was concentrated, and the excess TFA was removed by azeotropy with acetonitrile (50 mL. times.5) and TFA and dried in vacuo to give L-1 as a colorless oil (13.2g) which was used in the next step without purification. MS (ESI) M/z [ M + NH4]+Theoretical 242.1, found 242.5.
(3) Synthesis of intermediate NC-4-01
Figure BDA0002883820160000692
N2Tris (10.0g, 85.2mmol) was dissolved in DMSO (70mL) under an atmosphere, 5N NaOH solution (330mg, 0.83mmol) was added, and the mixture was slowly poured inTert-butyl acrylate (36.0g, 280.9mmol) was added dropwise and the reaction stirred at 25 ℃ for 24 hours. TLC (petroleum ether/EtOAc: 1/1, R)f0.7) indicates that the starting material was consumed. Quenched by addition of saturated ammonium chloride solution (100mL), extracted with EtOAc (100 mL. times.3), the organic phases were combined and washed with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (petroleum ether/EtOAc. 3/1) gave NC-4-01 as a colorless oil (8.07g, 19.3% yield). MS (ESI) M/z [ M + H]+Theoretical 506.3, found 506.5.
(4) Synthesis of intermediate NC-4-02
Figure BDA0002883820160000693
N2HATU (8.5g, 22.3mmol), DMAP (450mg, 3.72mmol) and L-1(4.8g, 21.4mmol) were dissolved in DCM (200mL) under an atmosphere, cooled to 0-5 ℃ in an ice bath, stirred for 10 minutes, after which a solution of NC-4-01(9.40g, 18.6mmol) and DIEA (12.12g, 93.0mmol) in DCM (100mL) was slowly added dropwise to the reaction solution, and the reaction was stirred for 16 hours at 25 ℃. TLC (petroleum ether/EtOAc: 1/1, R)f0.6) showed substantial disappearance of starting material. Adding saturated ammonium chloride solution (300mL), quenching, separating, extracting with DCM (100 mL. times.2), combining organic phases, washing with saturated brine (200mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (petroleum ether/EtOAc. 3/1) gave NC-4-02 as a colorless oil (8.78g, 66.5% yield). MS (ESI) M/z [ M + H]+Theoretical 712.4, found 712.2.
(5) Synthesis of intermediate NC-4
Figure BDA0002883820160000701
NC-4-02(14.6g, 20.5mmol) was dissolved in DCM/TFA (160mL/80mL), stirred at 25 ℃ for 1h, and TLC showed substantial disappearance of starting material. Concentration under reduced pressure, azeotropic removal of excess TFA with acetonitrile (100 mL. times.3) and TFA, and drying in vacuo afforded NC-4(11.1g, 99.6%) as a colorless oil which was purified without further treatmentAnd then used in the next step. MS (ESI) M/z [ M + H]+Theoretical 544.2, found 544.2.
(6) Synthesis of intermediate TO-11-01
Figure BDA0002883820160000702
N2NC-4(1g, 1.84mmol) was dissolved in DCM (30mL) under an atmosphere, cooled to 0-5 ℃ in an ice bath, EDCI (1.16g, 6mmol), HOBt (750mg, 5.22mmol) and DIEA (1.43g, 11.04mmol) were added in sequence, stirred for 10 min, then GN-2(3g, 5.94mmol) was added, and the reaction was stirred at 25 ℃ for 16 h. TLC (DCM/MeOH ═ 10/1) showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (20mL), separated, extracted with DCM (30mL × 2), combined organic phases and washed with saturated brine (30mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-8/1) gave TO-11-01(1.1g, 30% yield) as a white solid.
(7) Synthesis of Compound TO-11
Figure BDA0002883820160000711
TO a solution of TO-11-01(1g, 0.5mmol) in MeOH (20mL) was added 10% Pd/C (200mg), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 1 hour. TLC detection, essentially no starting material, filtration, washing of the filter cake with MeOH (10mL), and concentration of the filtrate to give the crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-11(620mg, 65% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.94(d,J＝7.4Hz,4H),7.90-7.84(m,3H),7.79(d,J＝9.3Hz,2H),7.06(s,1H),5.18(d,J＝2.9Hz,3H),4.94(dd,J＝11.1,3.1Hz,3H),4.51(d,J＝8.4Hz,3H),4.34-4.18(m,6H),4.05-4.03(m,4H),4.03-3.97(m,10H)3.84(dd,J＝19.4,8.7Hz,5H),3.79-3.69(m,4H),3.54–3.48(m,15H),3.47–3.40(m,8H),3.38–3.32(m,8H),3.09–3.24(m,7H),2.27-2.36(m,8H),2.06(s,9H),1.96(s,9H),1.85(s,9H),1.74(s,9H),1.13(d,J＝6.9Hz,9H).
MS(ESI):m/z[1/2M+H]+Theoretical value 958.4, found value 958.5
EXAMPLE 12 Synthesis of Compound TO-12, and phosphoramidite Compound TP-12
This example synthesizes one diastereomer of TO-12 and TP-12 according TO the following procedure.
(1) Synthesis of intermediate GC-4-01
Figure BDA0002883820160000712
N2DIC (60g, 0.48mol) was dissolved in tert-butanol (40.8g, 1.44mol) under an atmosphere, CuCl (480mg, 4.8mmol) was added, and the mixture was reacted at 25 ℃ for 5 days in the absence of light. DCM (200mL) was added for dilution, celite was filtered, and the filtrate was concentrated to give a dark green liquid (99 g). A dark green liquid (68g, 0.34mol) was dissolved in DCM (400mL) and 2, 2-dimethyl-3-hydroxypropionic acid (13.37g, 0.11mol), N2The reaction was refluxed for 16 hours under an atmosphere. TLC detected the starting material had substantially disappeared and concentrated to give a crude product which was purified by column chromatography (petroleum ether/EtOAc: 6/1) to give GC-4-01 as a pale yellow oil (12.3g, 62% yield). MS (ESI) M/z [ M + H]+Theoretical 175.1, found 175.1.
(2) Synthesis of intermediate GC-4-02
Figure BDA0002883820160000721
N2GC-4-01(12.3g, 71mmol) was dissolved in DMF (300mL) under an atmosphere, the temperature was reduced to 0-5 ℃ in an ice bath, NaH (4.26g, 106mmol) was added in portions, followed by 1-bromo-2-benzyloxyethane (15.2g, 71mmol) and the reaction was allowed to proceed to 25 ℃ for 16 hours. TLC detection of a small amount of starting material remained, quenched by addition of water (20mL), poured into EtOAc (600mL), washed with water (500 mL. times.3), washed with saturated brine (300mL), and washed with anhydrous Na2SO4Dried, filtered, concentrated and purified by column chromatography (petroleum ether/EtOAc: 20/1) to yield GC-4-02(7.8g, 36% yield) as a colorless oil. MS (ESI) M/z [ M + NH4]+Theoretical 326.2, found 326.1.
(3) Synthesis of intermediate GC-4-03
Figure BDA0002883820160000722
To a solution of GC-4-02(7.8g, 25.3mmol) in methanol (100mL) was added 5 drops of 1N hydrochloric acid and 10% Pd/C (1.56g), H2The displacement was carried out three times, and the reaction was carried out at 40 ℃ for 5 hours. The TLC detection shows that the raw material is basically disappeared. Filtration was carried out, the filter cake was washed with MeOH (20mL), and the filtrate was concentrated to give GC-4-03 as a colorless oil (5.3g, yield: 96%). MS (ESI) M/z [ M + H]+Theoretical 219.2, found 219.0.
(4) Synthesis of intermediate GC-4
Figure BDA0002883820160000731
N2GN-1-01(9.46g, 24.3mmol) and GC-4-03(5.3g, 24.3mmol) were dissolved in DCM (150mL) under an atmosphere, TMSOTf (2.7g, 12.2mmol) was added, and the reaction was carried out at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. Quench with saturated aqueous sodium bicarbonate, adjust pH to 9, extract with DCM (2 × 100mL) to remove impurities. The aqueous phase was adjusted to pH 3 by addition of 2N hydrochloric acid, extracted with DCM (150 mL. times.3), the organic phases combined, anhydrous Na2SO4Drying, filtering, concentrating, and vacuum drying to obtain white solid GC-4(6.3g, yield 53%), MS (ESI) M/z [ M + H ]]+Theoretical 492.2, found 492.1.
(5) Synthesis of intermediate TO-12-01
Figure BDA0002883820160000732
N2GC-4(3.72g, 7.56mmol) was dissolved in DMF (50mL) under ambient conditions, cooled in AN ice bath to 0-5 ℃, HATU (2.7g, 7.5mmol) and DIEA (2.5mL, 15.1mmol) were added, stirred for 10 min, followed by AN-1(TFA salt, 1.6g, 1.89mmol), warmed to 25 ℃ and stirred for 3 h. TLC showed substantial disappearance of starting material, diluted with EtOAc (400mL) and washed with water (200 mL. times.3)Saturated brine (200ml) washing, anhydrous Na2SO4Drying, filtering and concentrating. Purification by column chromatography (DCM/MeOH-30/1) gave TO-12-01(1.46g, 44% yield) as a white solid. MS (ESI) M/z [1/2M + H]+Theoretical 878.9, found 878.6.
(6) Synthesis of intermediate TO-12-02
Figure BDA0002883820160000741
TO a solution of TO-12-01(1.46g, 0.83mmol) in methanol (40mL) was added 10% Pd/C (150mg), and the mixture was replaced with hydrogen three times TO conduct a reaction at 25 ℃ for 2 hours. The TLC detection shows that the raw material is basically disappeared. Filtration was carried out, the filter cake was washed with MeOH (20mL), and the filtrate was concentrated TO give TO-12-02(1.35g, yield: 98%) as a white solid. MS (ESI) M/z [1/2M + H]+Theoretical 833.9, found 833.7.
(7) Synthesis of Compound TO-12
Figure BDA0002883820160000742
N2TO-12-02(1.35g, 0.81mmol) was dissolved in DCM (40mL) under ambient conditions, cooled TO 0-5 ℃ in an ice bath, EDCI (173mg, 0.9mmol) and HOBT (116mg, 0.86mmol) were added and stirred for 10 min, followed by diglycolamine (130mg, 1.2mmol) and DIEA (315mg, 2.44mmol), warmed TO 25 ℃ and stirred for 3 h. TLC showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (20mL), separated, extracted with DCM (30 mL. times.2), combined organic phases and washed with saturated brine (30mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-8/1) gave TO-12 as a white solid (910mg, 63% yield).
1H NMR(400MHz,DMSO-d6)δ7.88-7.73(m,5H),7.42-7.29(m,3H),5.18(d,J＝3.1Hz,3H),4.98-4.89(m,3H),4.51(t,J＝8.2Hz,3H),4.24-4.14(m,3H),3.99(s,10H),3.91-3.79(m,6H),3.78-3.64(m,6H),3.61-3.53(m,6H),3.52-3.42(m,13H),3.18(m,2H),2.99(br s,3H),2.06(s,9H),1.96(s,9H),1.85(s,9H),1.74(s,9H),1.63-1.54(m,2H),1.51-1.43(m,2H),1.37-1.24(m,4H),1.06-0.90(m,18H).
MS(ESI):m/z[1/2M+H]+Theoretical 877.4, found 877.9.
EXAMPLE 13 Synthesis of Compound TO-13, and phosphoramidite Compound TP-13
This example synthesizes one diastereomer of TO-13 and TP-13 according TO the following procedure.
(1) Synthesis of intermediate GC-3-01
Figure BDA0002883820160000751
N22-mercaptoethanol (5g, 64.2mmol) and tert-butyl acrylate (8.2g, 64.2mmol) were mixed under an atmosphere, triethylamine (4.2g, 41.58mmol) was added thereto, the mixture was heated to 45 ℃ and stirred for 48 hours. The TLC detection shows that the raw material is basically disappeared. Water (100mL) was added to the reaction mixture, extraction was performed with DCM (100 mL. times.3), and the organic phases were combined and washed with saturated brine (100mL), Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (petroleum ether/ethyl acetate 5/1) gave GC-3-01 as a colorless oil (11g, 83% yield).
(2) Synthesis of intermediate GC-3-02
Figure BDA0002883820160000752
N2GC-3-01(3.7g,18mmol) and GN-1-01(4.4g, 21.6mmol) were dissolved in DCM (100mL) under ambient conditions, TMSOTf (0.8g, 3.6mmol) was added, and the reaction was carried out at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. Add saturated sodium bicarbonate solution (100mL) quench, separate, extract with DCM (2 × 100mL), combine the organic phases and wash with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product, which was purified by silica gel column chromatography (petroleum ether/EtOAc. 1/2) to give GC-3-02 as a white solid (6.77g, 68% yield).
(3) Synthesis of intermediate GC-3
Figure BDA0002883820160000753
GC-3-02(6.77g, 12.6mmol) was dissolved in DCM (60mL), TFA (30mL) was added, and the reaction was carried out at 25 ℃ for 4 hours. The TLC starting material essentially disappeared. The reaction was concentrated and the excess TFA was removed by azeotropy with acetonitrile (100 mL. times.3) and TFA to give the crude product. Purification by silica gel column chromatography (petroleum ether/EtOAc ═ 1/5) gave GC-3(2.87g, 48% yield).
(4) Synthesis of intermediate AN-1
Figure BDA0002883820160000761
AN-1-04(1.85g, 1.85mmol) was dissolved in DMF (20mL), TBAF (1.49g, 5.5mmol) was added, and stirring was carried out at 25 ℃ for 6 hours. TLC detection of the starting material was essentially absent and no work-up was required and the solution was used directly in the next step.
(5) Synthesis of intermediate TO-13-01
Figure BDA0002883820160000762
N2GC-3(2.74g, 5.72mmol) was dissolved in THF (20mL) under ambient conditions, cooled in AN ice bath to 0-5 ℃, EDCI (1.16g, 6mmol) and HOBt (0.75g, 5.5mmol) were added and stirred for 10 min, followed by AN-1 in DMF and DIEA (1.43g, 11.08mmol), warmed to 25 ℃ and stirred for 16 h. TLC showed substantial disappearance of starting material, the reaction was concentrated and H was added2O (100mL), extracted with DCM (100 mL. times.3), the combined organic phases washed with saturated brine (100mL), Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-13-01(1.6g, 50% yield) as a white solid.
(6) Synthesis of intermediate TO-13-02
Figure BDA0002883820160000771
TO a solution of compound TO-13-01(1.6g, 0.93mmol) in MeOH (100mL) was added 10% Pd/C (1g), Pd (OH)2C (1g) and ammonium acetate (1.17g, 18.57mmol), H2The displacement was performed 3 times, and the reaction was carried out at 25 ℃ for 10 hours. The TLC detection shows that the raw material is basically disappeared. Filter, wash the filter cake with MeOH (20mL), and concentrate to give crude. The crude product was purified by silica gel column chromatography (DCM/MeOH ═ 7/1) TO give TO-13-02(600mg, yield 40%) as a white solid.
(7) Synthesis of Compound TO-13
Figure BDA0002883820160000772
N2TO-13-02(600mg, 0.37mmol) was dissolved in DCM (20mL) under an atmosphere, cooled TO 0-5 ℃ in ice bath, EDCI (92mg, 0.4mmol) and HOBt (55mg, 0.48mmol) were added, stirred for 10 min, subsequently trans 4-aminocyclohexanol (75mg, 0.34mmol) and DIEA (95mg, 0.74mmol) were added, and the reaction was stirred for 16 h at 25 ℃. TLC showed substantial disappearance of starting material, quenched by addition of saturated ammonium chloride solution (20mL), separated, extracted with DCM (30 mL. times.2), combined organic phases and washed with saturated brine (30mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-13(256mg, 40% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.00(dd,J＝14.3,8.2Hz,2H),7.87(t,J＝5.3Hz,2H),7.83(d,J＝9.2Hz,3H),7.68(d,J＝7.7Hz,1H),5.21(d,J＝3.2Hz,3H),4.96(dd,J＝11.2,3.3Hz,3H),4.55(d,J＝8.4Hz,3H),4.19(m,2H),4.04(s,9H),3.92-3.78(m,7H),3.63–3.57(m,4H),3.55–3.39(br m,9H),3.39–3.32(m,2H),3.05–2.94(m,4H),2.59–2.72(m,13H),2.44–2.35(m,4H),2.31(t,J＝7.2Hz,2H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.78(s,9H),1.74-1.66(m,2H),1.63–1.51(m,2H),1.47-1.29(m,6H),1.23-1.11(m,4H).
MS(ESI):m/z[1/2M+H]+Theoretical 864.3, found 864.5.
EXAMPLE 14 Synthesis of Compound TO-14, and phosphoramidite Compound TP-14
This example synthesizes one diastereomer of TO-14 and TP-14 according TO the following procedure.
(1) Synthesis of intermediate GN-3
Figure BDA0002883820160000781
To a solution of GN-3-01(25.0g, 39.0mmol) in THF (300mL) was added p-toluenesulfonic acid monohydrate (7.4g, 39.0mmol) and 10% Pd/C (2.66g), H2Displacement 3 times, stirring 3h at 25 ℃, TLC (DCM/MeOH-10/1, R)f0.5) showed substantial disappearance of starting material, which was filtered and concentrated to give GN-3 as a white solid (25.18g, yield 93.4%).
(2) Synthesis of intermediate TO-14-01
Figure BDA0002883820160000782
In N2NC-4(1.01g, 2.0mmol) was dissolved in DCM (50mL) under ambient conditions, cooled in an ice bath to 0-5 deg.C, EDCI (891mg, 6.6mmol) and HOBt (1.53g, 6.6mmol) were added, stirring was carried out for 10 min, followed by GN-3(4.56g, 6.6mmol) and DIEA (1.55g, 12.0 mmol). The reaction was stirred for 16 hours while warming to 25 ℃. TLC to check the completion of the reaction, add saturated ammonium chloride solution (50mL), quench, separate, extract with DCM (50 mL. times.2), combine the organic phases and wash with saturated brine (50mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-14-01(1.81g, 45.7% yield) as a white solid.
(3) Synthesis of Compound TO-14
Figure BDA0002883820160000791
TO a solution of TO-14-01(1.81g, 0.90mmol) in MeOH (50mL) was added 10% Pd/C (360mg) and Pd (OH)2/C(360mg)，H2Replacing for three times, stirring at 25 deg.C for 3 hr, detecting by TLC until the raw material basically disappears, filtering, concentrating to obtain crude product, and purifying by reverse phase preparation to obtain white pigmentTO-14 as a colored solid (1.16g, 67.4% yield).
1H NMR(400MHz,DMSO-d6)δ7.87(t,J＝5.3Hz,3H),7.83(t,J＝5.6Hz,3H),7.79(d,J＝9.2Hz,3H),7.08(s,1H),5.18(d,J＝3.2Hz,3H),4.94(dd,J＝11.2,3.2Hz,3H),4.51(d,J＝8.4Hz,3H),3.99(s,10H),3.90-3.79(m,5H),3.79-3.71(m,5H),3.58-3.49(m,15H),3.46-3.41(m,6H),3.44(dd,J＝10.7,5.8Hz,8H),3.24-3.11(m,12H),2.30(t,J＝6.2Hz,2H),2.26-2.18(m,12H),2.07(s,9H),1.96(s,9H),1.86(s,9H),1.74(s,9H).
MS(ESI):m/z[M+H]+Theoretical 1915.8, found 1916.3.
EXAMPLE 15 Synthesis of Compound TO-15, and phosphoramidite Compound TP-15
This example synthesizes one diastereomer of TO-15 and TP-15 according TO the following procedure.
(1) Synthesis of intermediate NC-5-01
Figure BDA0002883820160000792
In N22-chloroethoxy-2-ethoxydiethanol (15g, 88.9mmol) was dissolved in THF (400mL) under an atmosphere, cooled to 0-5 ℃ in an ice bath, NaH (3.9g, 97.8mmol) was added, stirring was carried out for 10 minutes, BnBr (15.2g, 88.9mmol) was added dropwise, and the reaction was stirred at 25 ℃ for 4 hours. TLC detection, essential disappearance of starting material, quenching with water (200mL), separating, extracting the aqueous phase with EtOAc (100 mL. times.3), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product. Purification by silica gel column chromatography (petroleum ether/EtOAc ═ 5/1) gave NC-5-01(19g, 82.6% yield) as a colorless oil.
(2) Synthesis of intermediate NC-5-02
Figure BDA0002883820160000801
Ethylenediamine (44g, 734mmol) was dissolved in anhydrous ethanol (250mL) and stirred, the temperature was raised to 80 ℃ and a solution of NC-5-01(19g, 73.4mmol) in anhydrous ethanol (250mL) was slowly added dropwise, and the reaction was carried out for 16 hours. TLC detection of the starting material was essentially lost, concentrated and toluene (100 mL. times.3) was added to azeotropically remove ethylenediamine to give crude NC-5-01(24g) which was used directly in the next reaction.
(3) Synthesis of intermediate NC-5-03
Figure BDA0002883820160000802
NC-5-02(16.7g, 58.9mmol) was dissolved in THF (500mL), potassium carbonate (65g, 471mmol) and tert-butyl bromoacetate (46g, 235mmol) were added, the reaction was stirred at 25 ℃ for 16 hours, the starting material was detected by TLC, filtered, concentrated to give a crude product, which was purified by silica gel column chromatography (petroleum ether/EtOAc ═ 5/1) to give NC-5-03(10g, 27% yield) as a colorless oil.
(4) Synthesis of intermediate NC-5
Figure BDA0002883820160000803
To 1, 4-dioxane (100mL) of compound NC-5-03(10g, 16mmol) was added concentrated hydrochloric acid (30mL), the temperature was raised to 60 ℃ and the reaction was carried out for 4 hours, and by TLC detection, the starting material was substantially disappeared, concentrated, and toluene (50 mL. times.3) was added to remove the excess solvent by azeotropic distillation, to obtain crude NC-5(8.3g) which was used directly in the next reaction.
(5) Synthesis of intermediate TO-15-01
Figure BDA0002883820160000811
At N2NC-5(1.2g, 2.6mmol) and GN-3(5.87g, 8.67mmol) were dissolved in DCM (100mL) under ambient conditions, cooled to 0-5 ℃ in an ice bath, PyBOP (4.7g, 9.1mmol) was added and DIEA (1.55g, 12.0mmol) was slowly added dropwise. The reaction was stirred for 16 hours while warming to 25 ℃. TLC to check the completion of the reaction, add saturated ammonium chloride solution (50mL), quench, separate, extract with DCM (50 mL. times.2), combine the organic phases and wash with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product. Layer of warp columnPurification by chromatography (DCM/MeOH — 8/1) gave TO-15-01(1.8g, 36% yield) as a white solid.
(6) Synthesis of Compound TO-15
Figure BDA0002883820160000812
TO a solution of the compound TO-15-01(1.2g, 0.6mmol) in methanol (100mL) was added 10% Pd/C (300mg), H2The displacement was carried out three times, and the reaction was carried out at 25 ℃ for 3 hours. TLC showed the starting material had substantially disappeared, filtered and concentrated TO give the crude product which was purified by column chromatography (DCM/MeOH/TEA 10/1/0.1) TO give TO-15(760mg, 69.2% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.48(t,J＝5.3Hz,1H),8.08(t,J＝4.9Hz,2H),7.99-7.91(m,3H),7.84(d,J＝9.2Hz,3H),5.22(d,J＝3.2Hz,3H),4.98(dd,J＝11.2,3.3Hz,3H),4.54(d,J＝8.5Hz,3H),4.03(s,10H),3.95(br s,3H),3.91-3.84(m,6H),3.82-3.73(m,7H),3.61-3.55(m,4H),3.54(m,4H),3.52-3.48(m,7H),3.45-3.42(m,2H),3.41-3.37(m,6H),3.32-3.25(m,10H),3.19(m,6H),3.00-2.93(m,2H),2.33-2.26(m,6H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.78(s,9H).
MS(ESI):m/z[M+H]+Theoretical 914.9, found 915.1.
EXAMPLE 16 Synthesis of Compound TO-16, and phosphoramidite Compound TP-16
This example synthesizes one diastereomer of TO-16 and TP-16 according TO the following procedure.
(1) Synthesis of intermediate GN-11-01
Figure BDA0002883820160000821
Reacting 2- [2- (2-aminoethoxy) ethoxy]Ethanol (8.5g, 56.9mmol) was dissolved in THF (200mL) and water (100mL), sodium bicarbonate (5.3g, 62.6mmol) was added, and CbzCl (10.69g, 62.6mmol) was slowly added dropwise. After 16 hours at 25 deg.C, TLC checked that the starting material had substantially disappeared, separated, extracted by adding EtOAc (100 mL. times.3), and the organic phases were combined and washed with saturated brine (150mL)Anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (EtOAc) afforded GN-11-01 as a colorless oil (15g, 93.7% yield).
(2) Synthesis of intermediate GN-11-02
Figure BDA0002883820160000822
N2GN-11-01(16g, 56.47mmol) and GN-1-01(19.98g, 51.34mmol) were added to DCM (100mL) under an atmosphere followed by con.H2SO4(2.5g, 25.67mmol), and reacted at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. Add saturated sodium bicarbonate solution (100mL) quench, separate, extract with DCM (2 × 100mL), combine the organic phases and wash with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product, which was purified by silica gel column chromatography (DCM/MeOH — 20/1) to give GN-11-02 as a white solid (17g, 54.8% yield).
(3) Synthesis of intermediate GN-11
Figure BDA0002883820160000831
To a solution of GN-11-02(7g, 11.4mmol) in MeOH (200mL) was added 10% Pd/C (700mg), H23 times displacement, stirring for 3h at 25 ℃, TLC (DCM/MeOH 10/1, R)f0.5) showed the starting material had substantially disappeared, filtered and concentrated to give GN-11 as a white solid (5.2g, yield 95.2%).
(4) Synthesis of intermediate TO-16-01
Figure BDA0002883820160000832
In N2NC-5(800mg, 1.75mmol) and GN-11(3.76g, 5.78mmol) were dissolved in DCM (50mL) under ambient conditions, cooled to 0-5 ℃ in an ice bath, PyBOP (3.2g, 6.13mmol) was added, and DIEA (1.8g, 14mmol) was slowly added dropwise. The reaction was stirred for 16 hours while warming to 25 ℃. TLC detection for substantial completion of the reaction, addQuenched with saturated ammonium chloride solution (50mL), separated, extracted with DCM (50 mL. times.2), combined organic phases and washed with saturated brine (50mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-16-01(1.7g, 53% yield) as a white solid.
(5) Synthesis of Compound TO-16
Figure BDA0002883820160000833
TO a solution of TO-16-01(1.0g, 0.54mmol) in MeOH (100mL) was added 10% Pd/C (300mg), H2Replacing for 3 times, stirring for 3 hours at 25 ℃, detecting by TLC that the raw materials basically disappear, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH/TEA 10/1/0.1) gave TO-16(770mg, 81% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.55(s,1H),8.10(t,J＝5.7Hz,2H),7.82(d,J＝9.1Hz,3H),5.22(d,J＝3.4Hz,3H),4.97(dd,J＝11.2,3.4Hz,3H),4.54(d,J＝8.6Hz,3H),4.03(s,10H),3.94-3.83(m,4H),3.81-3.74(m,6H),3.60-3.55(m,6H),3.54(s,6H),3.51(br s,6H),3.51-3.49(m,12H),3.46-3.42(m,13H),3.27-3.22(m,8H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.77(s,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 874.4, found 874.5.
EXAMPLE 17 Synthesis of Compound TO-17, and phosphoramidite Compound TP-17
This example synthesizes one diastereomer of TO-17 and TP-17 according TO the following procedure.
(1) Synthesis of intermediate TO-17-01
Figure BDA0002883820160000841
In N2NC-5(1.0g, 2.19mmol) and GN-1(4.38g, 7.23mmol) were dissolved in DCM (100mL) under ambient conditions, cooled to 0-5 ℃ in an ice bath, PyBOP (3.99g, 7.67mmol) was added and DIEA (2.4g, 18.4mmol) was slowly added dropwise. Heating to 25 deg.CThe reaction was stirred for 16 hours. TLC to check the completion of the reaction, add saturated ammonium chloride solution (50mL), quench, separate, extract with DCM (50 mL. times.2), combine the organic phases and wash with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-17-01(2.18g, 45% yield) as a white solid.
(2) Synthesis of Compound TO-17
Figure BDA0002883820160000851
TO a solution of TO-17-01(1.0g, 0.59mmol) in MeOH (30mL) was added 10% Pd/C (300mg), H2Replacing for 3 times, stirring for 3 hours at 25 ℃, detecting by TLC that the raw materials basically disappear, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH/TEA-10/1/0.1) gave TO-17(560mg, 59.7% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.62-8.29(m,1H),8.06(t,J＝5.5Hz,2H),7.82(dd,J＝9.2,4.6Hz,3H),5.19(d,J＝3.4Hz,3H),4.94(dd,J＝11.2,3.4Hz,3H),4.50(d,J＝8.5Hz,3H),4.00(s,9H),3.98–3.94(m,2H),3.89-3.81(m,4H),3.79–3.71(m,7H),3.58-3.52(m,9H),3.50(s,6H),3.49-3.44(m,8H),3.43-3.35(m,12H),3.29-3.24(m,4H),3.23-3.18(m,4H),2.99-2.94(m,2H),2.07(s,9H),1.97(s,9H),1.86(s,9H),1.74(s,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 808.4, found 808.2.
EXAMPLE 18 Synthesis of Compound TO-18, and phosphoramidite Compound TP-18
This example synthesizes one diastereomer of TO-18 and TP-18 according TO the following procedure.
(1) Synthesis of intermediate TO-18-01
Figure BDA0002883820160000852
In N2NC-5(1.0g, 2.19mmol) and GN-2(3.8g, 7.5mmol) were dissolved in DCM (100mL) under an atmosphere and cooled in an ice bathTo 0-5 deg.C, PyBOP (3.9g, 7.5mmol) was added and DIEA (2.4g, 18.4mmol) was slowly added dropwise. The reaction was stirred for 16 hours while warming to 25 ℃. TLC to check the completion of the reaction, add saturated ammonium chloride solution (50mL), quench, separate, extract with DCM (50 mL. times.2), combine the organic phases and wash with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-18-01(2.2g, 53% yield) as a white solid.
(2) Synthesis of Compound TO-18
Figure BDA0002883820160000861
TO a solution of TO-18-01(1.9g, 0.99mmol) in MeOH (40mL) was added 10% Pd/C (300mg), H2Replacing for 3 times, stirring for 3 hours at 25 ℃, detecting by TLC that the raw materials basically disappear, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH/TEA-10/1/0.1) gave TO-18(1.5g, 83% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.61(d,J＝6.8Hz,1H),8.21(d,J＝7.7Hz,2H),8.14-7.89(m,3H),7.80(d,J＝9.2Hz,3H),5.18(d,J＝3.4Hz,3H),4.94(dd,J＝11.2,3.4Hz,3H),4.50(d,J＝8.5Hz,3H),4.34-4.20(m,3H),3.99(s,10H),3.90-3.80(m,3H),3.78-3.69(m,5H),3.57-3.51(m,4H),3.50(s,4H),3.48-3.44(m,8H),3.41-3.33(m,16H),3.23-3.09(m,8H),2.07(s,9H),1.96(s,9H),1.86(s,9H),1.74(s,9H),1.20-1.17(m,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 914.9, found 914.7.
(3) Synthesis of Compound TP-18
Figure BDA0002883820160000871
N2TO-18(500mg, 0.268mmol) was dissolved in dry DCM (7.5mL) under ambient conditions, DIEA (0.22mL, 1.34mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (0.12mL, 0.54mmol) in dry DCM (1mL) was slowly added dropwise with a syringe. Reaction at 25 deg.CFor 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and use saturated NaHCO for the organic phase3The solution (10mL), washed with brine (10mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-18(410mg, 74% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.13(d,J＝7.9Hz,2H),8.04-7.96(m,3H),7.89-7.80(m,4H),5.21(d,J＝3.4Hz,3H),4.97(dd,J＝11.2,3.4Hz,3H),4.54(d,J＝8.4Hz,3H),4.33-4.24(m,3H),4.03(s,10H),3.87(dt,J＝11.0,9.0Hz,3H),3.82-3.66(m,6H),3.63-3.44(m,23H),3.44-3.36(m,8H),3.28-3.14(m,12H),2.63(m,6H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.77(s,9H),1.21-1.11(m,21H)；
31P NMR(162MHz,DMSO-d6)δ147.90。
EXAMPLE 19 Synthesis of Compound TO-19, and phosphoramidite Compound TP-19
This example synthesizes one diastereomer of TO-19 and TP-19 according TO the following procedure.
(1) Synthesis of intermediate TO-19-01
Figure BDA0002883820160000881
In N2GN-2(720mg, 1.42mmol) and NC-3(200mg, 0.43mmol) were dissolved in DCM (30mL) under an atmosphere, cooled to 0-5 ℃ in an ice bath, EDCI (204mg, 1.51mmol), HOBt (272mg, 4.42mmol) and DIEA (334mg, 2.59mmol) were added in this order, and stirred for 16 hours at 25 ℃ with TLC showing that the starting materials were almost disappeared. Adding saturated ammonium chloride solution (30mL), quenching, separating, extracting with DCM (50 mL. times.2), combining organic phases and washing with saturated brine (50mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-19-01(450mg, 54.6% yield) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 1925.9, found 1926.2.
(2) Synthesis of intermediate TO-19-02
Figure BDA0002883820160000882
At N2Under an atmosphere, L1(94mg, 0.42mmol) was dissolved in DCM (10mL), cooled TO 0-5 ℃ in an ice bath, HATU (160mg, 0.42mmol), DMAP (8.5mg, 0.07mmol) and DIEA (225mg, 1.75mmol) were added sequentially, stirred for 10 min, TO-19-01(0.68g, 0.35mmol) was added, heated TO 25 ℃ and stirred for 16 h, and TLC showed that the starting material was substantially lost. Adding saturated ammonium chloride solution (20mL), quenching, separating, extracting with DCM (30 mL. times.2), combining organic phases and washing with saturated brine (50mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-19-02(395mg, 53% yield) as a white solid.
(3) Synthesis of Compound TO-19
Figure BDA0002883820160000891
TO a solution of TO-19-02(1.04g, 0.49mmol) in MeOH (30mL) was added 10% Pd/C (200mg) and Pd (OH)2/C(100mg)，H2The mixture was displaced 3 times and stirred at 25 ℃ for 3 hours. TLC showed the starting material had substantially disappeared, filtered, and concentrated TO give a crude product that was purified by column chromatography (DCM/MeOH/TEA 10/1/0.1) TO give TO-19(640mg, 64% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.87-7.78(m,9H),7.06(s,1H),5.18(d,J＝3.2Hz,3H),5.07(br s,1H),4.95(dd,J＝11.2,3.3Hz,3H),4.51(d,J＝8.5Hz,3H),4.21(m,3H),3.99(s,8H),3.89-3.79(m,3H),3.77-3.69(m,3H),3.58-3.40(m,20H),3.34(t,J＝5.8Hz,8H),3.28(t,J＝6.3Hz,6H),3.15(m,6H),2.28(t,J＝6.4Hz,2H),2.10-2.02(m,15H),1.96(s,9H),1.86(s,9H),1.74(s,9H),1.47-1.38(m,12H),1.24-1.18(m,6H),1.12(d,J＝7.0Hz,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 1021.5, found 1021.8.
(4) Synthesis of Compound TP-19
Figure BDA0002883820160000892
N2TO-19(700mg, 0.34mmol) was dissolved in dry DCM (10mL) under ambient conditions, DIEA (0.28mL, 1.7mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (0.15mL, 0.68mmol) in dry DCM (1mL) was slowly added dropwise with a syringe. The reaction was carried out at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and use saturated NaHCO for the organic phase3The solution (10mL) was washed with brine (10mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) gave TP-19 as a white solid (380mg, 49.5% yield).
1H NMR(400MHz,DMSO-d6)δ7.88-7.80(m,9H),7.10-7.07(m,1H),5.18(d,J＝3.2Hz,3H),4.95(dd,J＝11.3,3.2Hz,3H),4.52(d,J＝8.4Hz,3H),4.25-4.17(m,3H),4.00(s,9H),3.89-3.79(m,3H),3.78-3.62(m,6H),3.59-3.51(m,8H),3.51-3.41(m,14H),3.38-3.32(m,7H),3.28-3.26(m,4H),3.22(s,2H),3.20-2.99(m,10H),2.73(t,J＝5.8Hz,2H),2.31-2.26(m,2H),2.09-2.05(m,13H),1.96(s,9H),1.86(s,9H),1.74(s,9H),1.47-1.38(m,12H),1.25-1.19(m,6H),1.13-1.08(m,21H)；
31P NMR(162MHz,DMSO-d6)δ147.90。
EXAMPLE 20 Synthesis of the Compound TO-20, and phosphoramidite Compound TP-20
This example synthesizes one diastereomer of TO-20 and TP-20 according TO the following procedure.
(1) Synthesis of intermediate GN-15-01
Figure BDA0002883820160000901
In N22, 2-dimethyl-3-hydroxypropionic acid (5.0g, 42.4mmol) was dissolved in DMF (50mL) under an atmosphere and potassium carbonate (17.55g, 127.2mmol) was added withThen, benzyl bromide (7.98g, 46.64mmol) was added dropwise, and the reaction was carried out at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. The reaction mixture was diluted with EtOAc (300mL), washed with water (100 mL. times.3) and saturated brine (100mL), and washed with anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (petrol ether/EtOAc. 4/1) gave GN-15-01 as a colourless oil (9.2g, 92% yield).
(2) Synthesis of intermediate GN-15-02
Figure BDA0002883820160000911
N2GN-1-01(7.0g, 18mmol) and GN-15-01(4.5g, 21.6mmol) were added to DCM (100mL) under an atmosphere, TMSOTf (2.0g, 9mmol) was added, and the reaction was carried out at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. Add saturated sodium bicarbonate solution (100mL) quench, separate, extract with DCM (100mL × 2), combine the organic phases and wash with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated to give the crude product, which was purified by silica gel column chromatography (DCM/MeOH ═ 40/1) to give GN-15-02(9.0g, 93% yield) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 538.2, found 538.2.
(3) Synthesis of intermediate GN-15-03
Figure BDA0002883820160000912
To a solution of GN-15-02(9.0g, 16.76mmol) in methanol (100mL) was added 10% Pd/C (900mg), H2The displacement was carried out three times, and the reaction was carried out at 25 ℃ for 2 hours. TLC detection starting material was essentially lost, filtered and concentrated to give GN-15-03 as a white solid (6.6g, 88% yield). MS (ESI) M/z [ M + H]+Theoretical 448.2, found 448.1.
(4) Synthesis of intermediate GN-15-04
Figure BDA0002883820160000913
In N2GN-15-03(5.8g, 13mmol) and N-t-butoxycarbonyl-1, 4-butanediamine (2.7g, 14.3mmol) were dissolved in DCM (100mL) under an atmosphere, EDCI (3.75g, 19.5mmol), DIEA (5.0g, 39mmol) and DMAP (317mg, 2.6mmol) were added in this order at a temperature of 0 to 5 ℃ in an ice bath, and the mixture was stirred at 25 ℃ for 16 hours. TLC showed substantial disappearance of starting material. Quenched by addition of water (100mL), separated, extracted with DCM (100 mL. times.2), combined organic phases and washed with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (petroleum ether/EtOAc. 10/1) gave GN-15-04(5.0g, 63% yield) as a white solid. MS (ESI) M/z [ M + H]+Theoretical 618.3, found 618.2.
(5) Synthesis of intermediate GN-15
Figure BDA0002883820160000921
GN-15-04(4.55g, 7.37mmol) was dissolved in DCM (40mL), and TFA (20mL) was added and reacted at 25 ℃ for 2 hours. The TLC detection shows that the raw material is basically disappeared. The reaction was concentrated and excess TFA was removed by azeotropy with acetonitrile (100 mL. times.3) and TFA to give GN-15 as a brown oil (TFA salt, 5.2 g). MS (ESI) M/z [ M + H]+Theoretical 518.3, found 518.2.
(6) Synthesis of intermediate TO-20-01
Figure BDA0002883820160000922
In N2NC-4(1.11g, 2.04mmol) and GN-15(5.2g, 7.37mmol) were dissolved in DMF/DCM (20mL/100mL) under ambient conditions, cooled to 0-5 ℃ in an ice water bath, PyBOP (4.24g, 8.16mmol) was added and DIEA (3.95g, 30.6mmol) was slowly added dropwise. The reaction was stirred for 16 hours while warming to 25 ℃. LCMS detected product formation. Quenched by adding saturated ammonium chloride solution (50mL), separated, extracted with DCM (100 mL. times.2), combined organic phases and washed with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-20-01(2.3g, 55% yield) as a white solid. MS (Mass Spectrometry)(ESI):m/z[M+H]+Theoretical 1021.5, found 1022.0.
(7) Synthesis of Compound TO-20
Figure BDA0002883820160000923
TO a solution of TO-20-01(1.8g, 0.88mml) in methanol (40mL) was added 10% Pd/C (360mg), H2The displacement was carried out three times, and the reaction was carried out at 25 ℃ for 1 hour. The TLC detected that the starting material had substantially disappeared. Filtration and concentration gave the crude product which was purified by column chromatography (DCM/MeOH/TEA 10/1/0.1) TO give TO-20(1.08g, 63% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.83-7.77(m,6H),7.26(t,J＝5.7Hz,3H),7.08(s,1H),5.19(d,J＝3.5Hz,3H),4.91(dd,J＝11.4,3.4Hz,3H),4.41(d,J＝8.4Hz,3H),4.04-3.95(m,10H),3.94-3.88(m,6H),3.68(d,J＝9.4Hz,6H),3.53-3.50(m,10H),3.45-3.41(m,3H),3.35-3.32(m,3H),3.29(d,J＝9.5Hz,3H),3.04-2.96(m,12H),2.29(t,J＝6.6Hz,2H),2.24(t,J＝6.4Hz,6H),2.07(s,9H),1.96(s,9H),1.86(s,9H),1.73(s,9H),1.41-1.27(m,12H),0.98(d,J＝4.1Hz,18H).
MS(ESI):m/z[1/2M+H]+Theoretical 976.5, found 976.7.
EXAMPLE 21 Synthesis of Compound TO-21, and phosphoramidite Compound TP-12
This example synthesizes one diastereomer of TO-21 and TP-21 according TO the following procedure.
(1) Synthesis of intermediate GN-13-01
Figure BDA0002883820160000931
In N2Under an atmosphere, 4-hydroxybenzylamine (10.07g, 81.77mmol) and Boc2O (19.5g, 89.35mmol) was dissolved in MeOH (300mL) and NaHCO was added3(17.5g, 20.8mmol), warming to 65 ℃ for 16 h, TLC (petroleum ether/EtOAc ═ 1/1) showed substantial disappearance of starting material, concentration, addition of water (100mL), EtOAc (100mL × 3) extraction, combining the organic phases and extraction with saturated common saltWashed with water (100mL), anhydrous Na2SO4Dried, filtered and concentrated to give GN-13-01 as a colorless oil (18.12g, 99.0% yield).
(2) Synthesis of intermediate GN-13-02
Figure BDA0002883820160000932
GN-13-01(18.12g, 81.2mmol) was dissolved in DMF (300mL), and bromoethanol (20.39g, 162.4mmol) and K were added in that order2CO3(33.7g, 244mmol) and NaI (2.44g, 16.24mmol), heating to 80 deg.C and stirring for 16 hours, TLC (Petroleum ether/EtOAc ═ 1/1) detecting substantial disappearance of starting material, concentrating, adding water (100mL), extracting with methyl tert-butyl ether (100 mL. times.3), combining organic phases and washing with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating, and purifying by column chromatography (petrol ether/EtOAc: 5/1) to obtain GN-13-02(11.3g, 52.1% yield) as a white solid, MS (ESI) M/z [ M + Na ]]+Theoretical 290.3, found 290.3.
(3) Synthesis of intermediate GN-13-03
Figure BDA0002883820160000941
Stock GN-13-02(11.3g, 42.3mmol) was dissolved in DCM (100mL), TFA (50mL) was added and stirred at 25 ℃ for 1 hour, TLC (petroleum ether/EtOAc ═ 1/1) showed substantial disappearance of the stock, concentrated, excess TFA was removed azeotropically with acetonitrile (100mL × 3) and TFA, water was added and lyophilized to give GN-13-03(TFA salt, 11.2g, theoretical yield) as a white solid.
(4) Synthesis of intermediate GN-13-04
Figure BDA0002883820160000942
In N2Dissolving Fmoc-glycine (12.12g, 40.8mmol) in DCM (300mL) under an atmosphere, cooling to 0-5 ℃ in an ice-water bath, adding TBTU (13.33g, 40.8mmol), stirring for 30 minutes, and reactingThe liquid became colorless and clear. GN-13-03(6.2g, 37.1mmol) and DIEA (29.93g, 185.5mmol) were dissolved in DCM (120mL) and DMF (20mL) and added slowly dropwise to the reaction. The reaction was stirred for 16 hours while warming to 25 ℃. TLC (DCM/MeOH ═ 10/1) showed the starting material was consumed and LCMS showed product formation. Adding saturated ammonium chloride solution (200mL), quenching, separating, extracting with DCM (100 mL. times.2), combining organic phases, washing with saturated saline (200mL), anhydrous Na2SO4Dried, filtered and concentrated. Adding acetone (300mL) and pulping for 1 hour, filtering, leaching the filter cake with a small amount of acetone, collecting the filter cake, and drying the filter cake in a vacuum oven at 45 ℃ for 3 hours to obtain a white solid compound GN-13-04(15.01g, yield 25.7%).
(5) Synthesis of intermediate GN-13-05
Figure BDA0002883820160000951
GN-13-04(9.99g, 22.4mmol) and GN-1-01(9.62g, 24.7mmol) were suspended in DCM (500mL), TMSOTf (6.15g, 26.7mmol) was slowly added dropwise, the reaction was stirred at 25 ℃ for 16 h, and TLC (EtOAc) showed substantial disappearance of the starting material. Adding saturated NaHCO3The solution (200mL) was quenched, separated, extracted with DCM (100 mL. times.2), the organic phases combined and washed with saturated brine (400mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. The crude product was recrystallized from EtOAc (400mL), crystallized at 25 ℃ for 1 hour, suction filtered, the filter cake rinsed with a small amount of EtOAc, collected and dried in a vacuum oven at 45 ℃ for 3 hours to yield GN-13-05 as a white solid (16.03g, 61.5% yield). MS (ESI) M/z [ M + H]+Theoretical 776.3, found 776.4.
(6) Synthesis of intermediate GN-13
Figure BDA0002883820160000952
GN-13-05(16.03g, 20.6mmol) was added to a mixed solution of DCM (210ml) and DMF (20ml), diethylamine (140ml) was added, and the reaction was stirred at 25 ℃ for 2 hours. Tlc (etoac) showed substantial disappearance of starting material. The reaction was concentrated, slurried with DCM/EtOAc 1/5(200mL), filtered, the filter cake rinsed with a small amount of EtOAc, and the filter cake collected as a white solid, GN-13(6.63g, 58.2% yield).
(7) Synthesis of intermediate TO-21-01
Figure BDA0002883820160000953
In N2NC-5(625mg, 1.37mmol) and GN-13(2.5g, 4.52mmol) were dissolved in a mixed solution of DCM (100mL) and DMF (20mL) under ambient conditions, PyBOP (2.35g, 4.52mmol) and DIEA (2.12g, 8.22mmol) were added, the reaction was stirred at 25 ℃ for 16 h, and TLC (DCM/MeOH-8/1) showed substantial disappearance of starting material. Adding saturated ammonium chloride solution (100mL), quenching, separating, extracting with DCM (100 mL. times.2), combining organic phases, washing with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH 8/1) gave the compound TO-21-01 as a white solid (1.12g, 34.2% yield).
(8) Synthesis of Compound TO-21
Figure BDA0002883820160000961
TO a solution of TO-21-01(1.0g, 0.48mmol) in MeOH (30mL) was added 10% Pd/C (200mg) and Pd (OH)2/C(150mg)，H2The reaction was stirred 3 times for 3h at 25 ℃ and TLC (DCM/MeOH ═ 10/1) material disappeared substantially, filtered, concentrated TO give crude product which was purified by column chromatography (DCM/MeOH/TEA ═ 10/1/0.1) TO give TO-21(700mg, 73.2% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.73(m,1H),8.41-8.29(m,5H),7.79(d,J＝9.5Hz,3H),7.12(d,J＝8.7Hz,6H),6.83(d,J＝8.3Hz,6H),5.19(d,J＝3.6Hz,3H),4.96(dd,J＝11.3,3.0Hz,3H),4.59(d,J＝9.1Hz,3H),4.22-4.13(m,6H),4.01(br s,16H),3.98-3,91(m,4H),3.91-3.82(m,4H),3.79-3.66(m,12H),3.52-3.42(m,15H),2.97(s,2H),2.07(s,9H),1.95(s,9H),1.85(s,9H),1.68(s,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 986.9, found 987.2.
EXAMPLE 22 Synthesis of the Compound TO-22, and the phosphoramidite Compound TP-22
This example synthesizes one diastereomer of TO-22 and TP-22 according TO the following procedure.
(1) Synthesis of intermediate TO-22-01
Figure BDA0002883820160000971
In N2NC-4(685mg, 1.26mmol) and GN-13(2.3g, 4.16mmol) were dissolved in DCM (50mL) under ambient conditions, the temperature was reduced to 0-5 ℃ in an ice bath, EDCI (562mg, 4.16mmol), HOBt (915mg, 4.79mmol) and DIEA (1.14g, 8.82mmol) were added in sequence, the temperature was raised to 25 ℃ and stirring was carried out for 16 hours, and TLC showed that the starting materials were substantially lost. Adding saturated ammonium chloride solution (30mL), quenching, separating, extracting with DCM (50 mL. times.2), combining organic phases and washing with saturated brine (50mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-8/1) gave TO-22-01(1.2g, 44% yield) as a white solid. MS (ESI) M/z [1/2M + H]+Theoretical 1075.4, found 1075.6.
(2) Synthesis of Compound TO-22
Figure BDA0002883820160000972
TO a solution of TO-22-01(700mg, 0.33mmol) in MeOH (70mL) was added 10% Pd/C (300mg) and Pd (OH)2/C(150mg)，H2The reaction was stirred 3 times at 25 ℃ for 3h, TLC (DCM/MeOH) ═ 8/1) starting material disappeared substantially, filtered and concentrated to give crude product. Purification by column chromatography (DCM/MeOH/TEA 10/1/0.1) gave TO-22(500mg, 73.5% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.28(t,J＝5.8Hz,3H),8.12(t,J＝5.6Hz,3H),7.84(d,J＝9.1Hz,3H),7.15(d,J＝8.6Hz,7H),6.86(d,J＝8.6Hz,6H),5.77-5.72(m,1H),5.23(d,J＝3.3Hz,3H),5.00(dd,J＝11.2,3.4Hz,3H),4.63(d,J＝8.5Hz,3H),4.20(d,J＝5.6Hz,6H),4.04(br s,14H),4.01-3.94(m,4H),3.94-3.84(m,3H),3.84-3.75(m,3H),3.72(d,J＝5.6Hz,6H),3.58-3.53(m,13H),3.41(dt,J＝37.4,5.1Hz,5H),2.35(dt,J＝19.0,6.4Hz,8H),2.10(s,9H),1.99(s,9H),1.89(s,9H),1.72(s,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 1030.4, found 1030.3.
(2) Synthesis of Compound TP-22
Figure BDA0002883820160000981
N2TO-22(500mg, 0.24mmol) was dissolved in dry DCM (7.5mL) under ambient conditions, DIEA (0.2mL, 1.2mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (107uL, 0.48mmol) in dry DCM (1mL) was slowly added dropwise with a syringe. The reaction was carried out at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3Quench (10mL), dilute with DCM (10mL), separate the layers, and use saturated NaHCO for the organic phase3The solution (10mL) was washed with brine (10mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-22(305mg, 62.7% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.24(t,J＝6.0Hz,3H),8.06(t,J＝5.7Hz,3H),7.80(d,J＝9.2Hz,3H),7.12(d,J＝8.1Hz,7H),6.83(d,J＝8.4Hz,6H),5.19(d,J＝3.3Hz,3H),4.96(dd,J＝11.3,3.3Hz,3H),4.59(d,J＝8.4Hz,3H),4.16(d,J＝5.4Hz,6H),4.00(s,14H),3.97-3.90(m,4H),3.90-3.81(m,3H),3.80-3.72(m,3H),3.68(d,J＝5.6Hz,8H),3.60-3.48(m,16H),3.48-3.44(m,2H),2.76-2.59(m,2H),2.39-2.25(m,9H),2.07(s,9H),1.95(s,9H),1.85(s,9H),1.68(s,9H),1.25-1.13(m,4H),1.09(dd,J＝6.6,4.7Hz,12H)；
31P NMR(162MHz,DMSO-d6)δ147.84；
MS(ESI):m/z[1/2M+H]+Theoretical 1130.4, found 1130.5.
EXAMPLE 23 Synthesis of Compound TO-23, and phosphoramidite Compound TP-23
This example synthesizes one diastereomer of TO-23 and TP-23 according TO the following procedure.
(1) Synthesis of intermediate GN-17-01
Figure BDA0002883820160000991
In N2GC-1(12g, 25.89mmol) was dissolved in DCM (200mL) under an atmosphere, the temperature was reduced to 0-5 ℃ in an ice water bath, HBTU (11.78g, 31mmol) and DIEA (10g, 77.67mmol) were added, stirring was carried out for 10 minutes, then N-t-butoxycarbonyl-1, 4-butanediamine (4.87g, 25.89mmol) was added, the temperature was raised to 25 ℃ and the reaction was stirred for 16 hours, and TLC showed that the starting material was substantially disappeared. Adding saturated ammonium chloride solution (100mL), quenching, separating, extracting with DCM (100 mL. times.2), combining organic phases, washing with saturated brine (100mL), anhydrous Na2SO4Dried, filtered and concentrated. Purification by column chromatography (DCM/MeOH-20/1) gave the compound GN-17-01 as a white solid (15g, 91% yield).
(2) Synthesis of intermediate GN-17
Figure BDA0002883820160000992
GN-17-01(15g, 23.67mmol) was dissolved in DCM (150mL), TFA (50mL) was added, stirring was carried out at 25 ℃ for 1 hour, TLC showed substantial disappearance of starting material, concentration was carried out, and excess TFA was removed by azeotropy with acetonitrile (100 mL. times.3) and TFA to give GN-17(TFA salt, 12.6g) as a foamy solid.
(3) Synthesis of intermediate TO-23-01
Figure BDA0002883820160000993
In N2NC-4(2.6g, 4.7mmol) was dissolved in DCM (200mL) under an atmosphere, cooled to 0-5 ℃ in an ice-water bath, HATU (5.6g, 14.83mmol) and DIEA (4.85g, 37.6mmol) were added and stirred for 20 minutes, followed by GN-17-01(8.45g, 15.5mmol) and the reaction was stirred at 25 ℃ for 4 hours.TLC detection, essential disappearance of the starting material, quenching with saturated ammonium chloride solution (50mL), separating, extracting with DCM (100 mL. times.2), combining the organic phases and washing with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-23-01(6.3g, 63.1% yield) as a white solid.
(4) Synthesis of Compound TO-23
Figure BDA0002883820160001001
TO a solution of TO-23-01(6.3g, 3.0mmol) in MeOH (100mL) was added 10% Pd/C (600mg) and Pd (OH)2/C(600mg)，H2The reaction was stirred for 3h at 25 ℃ with 3 times displacement, and the material was detected by TLC (DCM/MeOH 8/1) for substantial disappearance, filtered and concentrated to give crude product. Purification by column chromatography (DCM/MeOH/TEA-10/1/0.1) gave TO-23(4.5g, 75% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.88-7.81(m,9H),7.14(s,1H),5.21(d,J＝3.4Hz,3H),4.95(dd,J＝11.2,3.4Hz,3H),4.53(d,J＝8.5Hz,3H),4.07-3.97(m,9H),3.88(dt,J＝11.0,9.0Hz,3H),3.77-3.71(m,3H),3.63-3.50(m,24H),3.49-3.41(m,8H),3.38-3.35(m,2H),3.08-2.98(m,12H),2.35–2.25(m,14H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.78(s,9H),1.40-1.33(s,12H).
MS(ESI):m/z[1/2M+H]+Theoretical 1000.5, found 1000.3.
(5) Synthesis of Compound TP-23
Figure BDA0002883820160001002
N2TO-23(2.3g, 1.15mmol) was dissolved in dry DCM (40mL) under ambient conditions, DIEA (0.86mL, 5.2mmol) was added, and a solution of 2-cyanoethyl-N, N-diisopropylphosphoramidite (0.46mL, 2.1mmol) in dry DCM (2mL) was added slowly and dropwise with a syringe. The reaction was carried out at 25 ℃ for 1 hour. TLC detection, the material basically disappears, and saturated NaHCO is added3(20mL), quench, separate the liquid, use the organic phaseSaturated NaHCO3The solution (20mL) was washed with brine (20mL), dried over anhydrous MgSO4, filtered and concentrated to give the crude product. Purification by column chromatography (silica gel column pre-basified with 1.5% TEA/DCM, DCM/MeOH/TEA 15/1/0.1) afforded TP-23(1.8g, 71.1% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ7.91-7.79(m,9H),7.15(s,1H),5.21(d,J＝3.4Hz,3H),4.95(dd,J＝11.2,3.4Hz,3H),4.53(d,J＝8.5Hz,3H),4.06-3.97(m,9H),3.88(dt,J＝11.1,8.9Hz,3H),3.78-3.66(m,6H),3.63-3.41(m,36H),3.07-2.98(m,12H),2.76(t,J＝5.9Hz,2H),2.35-2.24(m,14H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.78(s,9H),1.40-1.33(m,12H),1.13(dd,J＝6.7,4.1Hz,12H)；
31P NMR(162MHz,DMSO-d6)δ147.81；
MS(ESI):m/z[1/2M+Na]+Theoretical 1122.5, found 1122.4.
EXAMPLE 24 Synthesis of Compound TO-24, and phosphoramidite Compound TP-24
This example synthesizes one diastereomer of TO-24 and TP-24 according TO the following procedure.
(1) Synthesis of intermediate GN-16-01
Figure BDA0002883820160001011
In N2Adding 2-mercaptoethanol (8g, 102.5mmol) into methyl acrylate (8.83g, 102.5mmol) under an atmosphere, cooling to 0-5 ℃ in an ice-water bath, slowly dropwise adding TEA (8.6mL, 66.6mmol), and heating to 45 ℃ for reacting for 16 hours after dropwise adding. The TLC detection shows that the raw material is basically disappeared. Cooling to below 30 deg.C, adding a drop of sodium hypochlorite, quenching, extracting with water (100mL), EtOAc (100mL), combining the organic phases, washing with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (petrol ether/EtOAc. 1/1) gave GN-16-01 as a colourless oil (16.7g, 99.4% yield). MS (ESI) M/z [ M + H]+Theoretical 165.1, found 165.2.
(2) Synthesis of intermediate GN-16-02
Figure BDA0002883820160001021
GN-16-01(16.7g, 101.83mmol) was added to ethylenediamine (61g, 1.02mmol), and the temperature was raised to 80 ℃ for reaction for 16 hours. The TLC detection shows that the raw material is basically disappeared. Concentration and azeotropic removal of excess ethylenediamine with acetonitrile (100 mL. times.3) afforded crude GN-16-02(21g) which was used directly in the next step. MS (ESI) M/z [ M + H]+Theoretical value 193.1, found value 193.1.
(3) Synthesis of intermediate GN-16-03
Figure BDA0002883820160001022
GN-16-02(21g, 103.6mmol) was dissolved in DCM (100mL) and NaHCO was added3The solution (100mL) was slowly added dropwise CbzCl (18.563g, 108.8mmol) and reacted at 25 ℃ for 3 hours. The TLC detection shows that the raw material is basically disappeared. The layers were separated, extracted with DCM (100 mL. times.2), the organic layers combined and washed with saturated brine (100mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-15/1) gave GN-16-03 as a white solid (14.5g, 41% yield). MS (ESI) M/z [ M + H]+Theoretical 327.1, found 327.2.
(4) Synthesis of intermediate GN-16-04
Figure BDA0002883820160001023
In N2GN-16-03(14.5g, 44.48mmol) and GN-1-01(15.73g, 40.4mmol) were dissolved in dry DCM (500mL) under an atmosphere, TMSOTf (12.56g, 56.56mmol) was slowly added dropwise, and the reaction was carried out at 25 ℃ for 16 hours. The TLC detection shows that the raw material is basically disappeared. Slowly adding saturated sodium bicarbonate (100mL) solution to quench, separating, extracting with DCM (100 mL. times.2), combining organic phases and washing with saturated brine (200mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purifying by column chromatography (DCM/MeOH: 40/1) to obtain white solidGN-16-04 as a colored solid (7.2g, 27% yield). MS (ESI) M/z [ M + H]+Theoretical 656.2, found 656.2.
(5) Synthesis of intermediate GN-16-05
Figure BDA0002883820160001031
GN-16-04(7.2g, 11mmol) is dissolved in DCM (100mL), cooled to 0-5 ℃ in an ice water bath, m-CPBA (6.6g, 38.5mmol) is slowly added in batches, and the temperature is raised to 25 ℃ for reaction for 3 hours. TL detects substantial disappearance of feedstock. After diluting with DCM (100mL), the mixture was washed with saturated sodium bicarbonate solution (100mL) and saturated brine (100mL), and dried over anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-30/1) gave GN-16-05 as a white solid (1.6g, 21% yield). MS (ESI) M/z [ M + H]+Theoretical 688.2, found 688.2.
(6) Synthesis of intermediate GN-16
Figure BDA0002883820160001032
To a solution of GN-16-05(1.6g, 2.3mmol) in MeOH (30mL) was added 10% Pd/C (320mg), H2The displacement was carried out three times, and the reaction was carried out at 25 ℃ for 1 hour. The TLC detection shows that the raw material is basically disappeared. Filtering to remove palladium carbon, and concentrating to obtain a crude product. Purification on reverse phase gave GN-16 as a white solid (760mg, 60% yield). MS (ESI) M/z [ M + H]+Theoretical 554.2, found 554.2.
(7) Synthesis of intermediate TO-24-01
Figure BDA0002883820160001033
In N2NC-4(187mg, 0.34mmol) was dissolved in DMF (10mL) under an atmosphere, cooled to 0-5 ℃ in an ice water bath, HATU (456mg, 1.2mmol) and DIEA (351mg, 2.72mmol) were added and stirred for 20 minutes, followed by GN-16(760mg, 1.37mmol), warmed to 25 ℃ and stirred for reaction for 3 hours. TLC detection, raw materialEssentially disappeared, quenched by addition of saturated ammonium chloride solution (30mL), extracted with DCM (30 mL. times.3), the organic phases combined and washed with saturated brine (50mL), anhydrous Na2SO4Drying, filtering and concentrating to obtain a crude product. Purification by column chromatography (DCM/MeOH-10/1) gave TO-24-01(450mg, 62% yield) as a white solid. MS (ESI) M/z [1/2M + H]+Theoretical 1075.4, found 1076.2.
(7) Synthesis of Compound TO-24
Figure BDA0002883820160001041
TO a solution of TO-24-01(450mg, 0.21mmol) in MeOH (20mL) was added 10% Pd/C (90mg) and Pd (OH)2/C(150mg)，H2The reaction was stirred for 1 hour at 25 ℃ with 3 substitutions, and the starting material was detected by TLC (DCM/MeOH) ═ 8/1) for substantial disappearance, filtered, and concentrated to give crude product. Purification by column chromatography (DCM/MeOH/TEA 10/1/0.1) gave TO-24(330mg, 76% yield) as a white solid.
1H NMR(400MHz,DMSO-d6)δ8.11(t,J＝5.3Hz,3H),7.96-7.88(m,6H),7.15(s,1H),5.22(d,J＝3.4Hz,3H),4.95(dd,J＝11.2,3.4Hz,3H),4.57(d,J＝8.5Hz,3H),4.12-3.99(m,14H),3.93(dt,J＝11.2,8.8Hz,5H),3.86-3.80(m,5H),3.56-3.52(m,14H),3.48-3.43(m,5H),3.38-3.34(m,3H),3.33-3.25(m,8H),3.10(br s,12H),2.36-2.30(m,2H),2.28(t,J＝6.5Hz,6H),2.10(s,9H),2.00(s,9H),1.89(s,9H),1.79(s,9H).
MS(ESI):m/z[1/2M+H]+Theoretical 1030.4, found 1029.9.
Example 25 RNAi agent duplexes conjugated to targeting ligands
The following RNAi agent duplexes were according to j.org.chem.2012,77, 4566-4577; phosphoramidite coupling techniques reported in curr.
To evaluate the efficacy of the targeting ligands of the invention as siRNA vectors for liver-targeted delivery in vivo, the RNAi agent duplex AD05488 (disclosed in CN 111343994a as having potent silencing ability against the lipid regulation-related gene ANGPTL 3) linked to an effective targeting ligand was used as a positive control, and the targeting ligands of the invention were conjugated to the nucleic acid portion (control sequence, expressed as PC) of AD05488, comparing the silencing efficacy against ANGPTL3 at equivalent levels. The targeting ligands are connected with 5 'end ribose (connected to ribose 5' hydroxyl residue) of the siRNA sense strand through a tail adaptor end phosphorothioate bond.
TABLE 1 Targeted ligand PC conjugated RNAi agent duplexes
Figure BDA0002883820160001051
Figure BDA0002883820160001061
In the above table, the first and second sheets are shown,
Figure BDA0002883820160001062
a targeting ligand corresponding to structure T-1 herein;
Figure BDA0002883820160001063
a targeting ligand corresponding to structure T-2 herein;
Figure BDA0002883820160001071
a targeting ligand corresponding to structure T-10 herein;
Figure BDA0002883820160001072
a targeting ligand corresponding to structure T-18 herein;
Figure BDA0002883820160001073
a targeting ligand corresponding to structure T-19 herein;
Figure BDA0002883820160001081
a targeting ligand corresponding to structure T-22 herein;
Figure BDA0002883820160001082
a targeting ligand corresponding to structure T-23 herein;
example 26 in vivo Activity of duplex ANGPTL3 RNAi Agents with Targeted ligands
Wild-type C57 model mice were used to evaluate the inhibition rate of the ANGPTL3 RNAi duplex conjugated to a targeting ligand on the expression level of ANGPTL3mRNA in liver tissue. RNAi agents linked to targeting ligand structures T-1, T-2, T-10, T-18, T-19, T-22, T-23, respectively, are combined in pharmaceutically acceptable buffers known in the art for subcutaneous injection. On the first day, each mouse was administered a single 200 μ L subcutaneous dose at a dose of 2.5mg/kg (mpk). The control group contained no RNAi agent. After 72 hours, the animals were euthanized and blood and liver tissue were collected.
The collected liver tissue was placed in TRIzol (Thermo Fisher Co., Ltd., product No. 15596026) and homogenized using a tissue grinder. Total RNA was extracted according to TRIzol protocol. Mu.g of total RNA was reverse transcribed into cDNA according to the reverse transcription kit (Vazyme, cat. No. R312-01/02). The expression level of ANGPTL3 in liver was detected by real-time quantitative PCR using 2 Xcha mQ SYBR qPCR Master Mix (Vazyme, cat # Q341-02) kit according to the instruction manual, and the reference gene was GAPDH gene.
The inhibition rate of siRNA against the target gene mRNA expression level was ═ 1- (expression amount of experimental ANGPTL3 mRNA/expression amount of experimental GAPHD mRNA)/(expression amount of control ANGPTL3 mRNA/expression amount of control GAPHD mRNA) ] × 100%.
The silencing efficiency of the RNAi agents described above is shown in table 2 below:
TABLE 2
Rnai agents Targeted ligands Percentage mRNA knockdown of ANGPTL3 at 72 hours
AD05488 Positive control ligand 75±6％
101PC T-1 87±6％
102PC T-2 74±9％
110PC T-10 81±12％
118PC T-18 82±5％
119PC T-19 67±5％
122PC T-22 91±2％
123PC T-23 77±2％
Compared with AD05488 connected with a positive control ligand, RNAi agents connected with targeting ligands T-1, T-10, T-18, T-22 and T-23 show higher target gene silencing efficiency.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.
Sequence listing
<110> Napeptide Co., Ltd
<120> a targeting ligand and its use for therapeutic nucleic acid conjugates
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 21
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gcucaacaua uuugaucagu a 21
<210> 2
<211> 19
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
uacugaucaa auauugagc 19

Claims (29)

1. A targeting ligand comprising the structure of formula I:
Figure FDA0002883820150000011
it comprises a tail connector, a branch framework and one or more than oneA plurality of linker arms, and one or more targeting groups;
wherein n is an integer of 1-4, and the number of branches of the branched skeleton is adapted to the number of groups formed by the targeting group and the connecting arm indicated by n.
2. The targeting ligand of claim 1, wherein the targeting moiety is attached to the linker arm via a glycosidic bond and is independently selected from the group consisting of: galactosyl, 2-amino-galactosyl, 2-acetyl amino galactosyl, 2-formamido-galactosyl, 2-propionamido-galactosyl.
3. The targeting ligand of claim 2, wherein the targeting moiety is 2-acetamido-galactosyl.
4. A targeting ligand according to any one of claims 1 to 3, wherein the branched backbone is linked to the linker arm via an amino residue and to the tail linker via a carbonyl residue, and is selected from the following structures:
Figure FDA0002883820150000012
wherein x and y are the same or different and are respectively selected from integers of 1-4;
Figure FDA0002883820150000013
wherein p and q are the same or different and are respectively selected from integers of 1-4.
5. The targeting ligand of claim 4, wherein the linker arm is linked to the branched backbone via a carbonyl residue, and is independently selected from the group consisting of:
Figure FDA0002883820150000014
wherein n is an integer of 1 to 3;
Figure FDA0002883820150000015
Figure FDA0002883820150000016
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000017
Figure FDA0002883820150000021
6. the targeting ligand of any one of claims 1 to 3, wherein the branched backbone is linked to the linker arm via a carbonyl residue and to the linker arm via an amino residue, and is selected from the group consisting of:
Figure FDA0002883820150000022
wherein m is an integer of 1-5;
Figure FDA0002883820150000023
wherein x and y are independently selected from integers of 1-3.
7. The targeting ligand of claim 6, wherein the linker arm is linked to the branched backbone through an amino residue, and is independently selected from the group consisting of:
Figure FDA0002883820150000024
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000025
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000026
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000027
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000028
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000031
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000032
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000033
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000034
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000035
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000036
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000037
wherein n is an integer of 1 to 3.
8. The targeting ligand of any one of claims 1-3, wherein the branched backbone is linked to the linker arm via a carbonyl residue and to the linker arm via an amino residue, and is selected from the group consisting of:
Figure FDA0002883820150000038
wherein x and y are independently selected from integers of 1-3, and x and y arey is not 2 at the same time;
Figure FDA0002883820150000039
9. the targeting ligand of claim 8, wherein the linker arm is linked to the branched backbone through an amino residue, independently having the structure b 18:
Figure FDA0002883820150000041
wherein n is an integer of 1 to 3.
10. The targeting ligand of any one of claims 1 to 3, wherein the branched backbone is linked to the linker arm via a carbonyl residue and to the linker arm via an amino residue, and has the structure a 6:
Figure FDA0002883820150000042
11. the targeting ligand of claim 10, wherein the linker arm is linked to the branched backbone through an amino residue, and is independently selected from the group consisting of:
Figure FDA0002883820150000043
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000044
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000045
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000046
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000047
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000048
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000049
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000051
wherein n is an integer of 1 to 2, and m is an integer of 1 to 5;
Figure FDA0002883820150000052
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000053
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000054
wherein n is an integer of 1 to 5;
Figure FDA0002883820150000055
wherein n is an integer of 1 to 3;
Figure FDA0002883820150000056
wherein n is an integer of 1 to 3.
12. A targeting ligand according to any one of claims 1 to 5, wherein the tail linker is linked to the branched backbone via an amino residue and is selected from the following structures:
Figure FDA0002883820150000057
wherein n is an integer of 1 to 2.
13. The targeting ligand of any one of claims 1 to 3 and 6 to 9, wherein the tail linker is linked to the branched backbone via a carbonyl residue, and is selected from the group consisting of:
Figure FDA0002883820150000058
Figure FDA0002883820150000059
wherein n is an integer of 1 to 3;
Figure FDA00028838201500000510
wherein n is an integer of 1 to 2;
Figure FDA00028838201500000511
Figure FDA0002883820150000061
14. the targeting ligand of any one of claims 1 to 3 and 10 to 11, wherein the linker is selected from the group consisting of structures b1H and b2H linked to the branched backbone via a carbonyl residue, and structure c6 linked via an alkyl residue CH2Connecting with the branch framework:
Figure FDA0002883820150000062
wherein n is an integer of 1 to 3;
Figure FDA0002883820150000063
Figure FDA0002883820150000066
wherein n is an integer of 1 to 2;
Figure FDA0002883820150000064
wherein n is an integer of 0 to 3.
15. The targeting ligand of any one of claims 1-14, wherein the targeting ligand is selected from at least one of the following structures:
Figure FDA0002883820150000065
Figure FDA0002883820150000071
Figure FDA0002883820150000081
Figure FDA0002883820150000091
Figure FDA0002883820150000101
Figure FDA0002883820150000111
Figure FDA0002883820150000121
Figure FDA0002883820150000131
16. the targeting ligand of any one of claims 1-15, wherein the targeting ligand is linked to a therapeutic nucleic acid.
17. The targeting ligand of any one of claims 1-16, wherein the therapeutic nucleic acid is a double-stranded nucleic acid.
18. The targeting ligand of any one of claims 1-17, wherein the therapeutic nucleic acid is an RNAi agent.
19. A medicament and pharmaceutically acceptable salts thereof, comprising the targeting ligand of any one of claims 1-18.
20. The agent of claim 19, wherein the agent and pharmaceutically acceptable salts thereof further comprise an RNAi agent; the targeting ligand is connected with the RNAi agent through a chemical group;
preferably, the chemical group is a covalent bond group; preferably, the targeting ligand is linked to the RNAi agent through a tail-terminal residue.
21. The agent and pharmaceutically acceptable salts thereof as claimed in claim 19, wherein the targeting ligand is linked to the RNAi agent through a tail linker terminal oxygen residue to form a phosphate group and/or a phosphorothioate group.
22. The pharmaceutical agent and pharmaceutically acceptable salts thereof, according to claim 19, wherein the RNAi agent is a therapeutic nucleic acid or an expression-inhibiting oligomer; preferably, the RNAi agent is a double-stranded RNAi agent.
23. The drug and its pharmaceutically acceptable salts according to claim 19, characterized in that it comprises at least one of the conjugates selected from the group consisting of:
Figure FDA0002883820150000141
Figure FDA0002883820150000151
Figure FDA0002883820150000161
Figure FDA0002883820150000171
Figure FDA0002883820150000181
Figure FDA0002883820150000191
Figure FDA0002883820150000201
Figure FDA0002883820150000211
Figure FDA0002883820150000221
wherein R of each conjugate comprises a therapeutic nucleic acid or an expression-inhibiting oligomer.
24. The drug and its pharmaceutically acceptable salts according to claim 23, wherein the conjugate is obtained by chemical reaction of the corresponding phosphoramidite compound to form a phosphate group, a phosphorothioate group linked/conjugated to a therapeutic nucleic acid or an expression-inhibiting oligomer;
Figure FDA0002883820150000222
Figure FDA0002883820150000231
Figure FDA0002883820150000241
Figure FDA0002883820150000251
Figure FDA0002883820150000261
Figure FDA0002883820150000271
Figure FDA0002883820150000281
Figure FDA0002883820150000291
Figure FDA0002883820150000301
25. the drug and pharmaceutically acceptable salts thereof according to claim 24, wherein the phosphoramidite compounds are linked/conjugated to each other by chemical reaction with a therapeutic nucleic acid or expression-inhibiting oligomer having a naked hydroxyl group in the presence of a base to form a phosphate, phosphorothioate group;
preferably, the therapeutic nucleic acid or expression-inhibiting oligomer is single-stranded.
26. The pharmaceutical agent and pharmaceutically acceptable salts thereof according to claim 24, wherein the phosphoramidite compound is obtained by contacting a phosphoramidite reagent with a corresponding compound as a starting material and then performing a phosphoramidite reaction;
Figure FDA0002883820150000311
Figure FDA0002883820150000321
Figure FDA0002883820150000331
Figure FDA0002883820150000341
Figure FDA0002883820150000351
Figure FDA0002883820150000361
Figure FDA0002883820150000371
Figure FDA0002883820150000381
27. use of a targeting ligand according to any of claims 1-18 for the manufacture of a medicament for the treatment of small nucleic acids.
28. A receptor cell comprising the targeting ligand of any one of claims 1-18.
29. The cell of claim 28, wherein the cell is a mammalian hepatocyte cell;
preferably, the cell is a human hepatocyte.
CN202110008013.3A 2020-09-30 2021-01-05 Targeting ligand and application thereof in therapeutic nucleic acid conjugate Pending CN114716489A (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN202110008013.3A CN114716489A (en) 2021-01-05 2021-01-05 Targeting ligand and application thereof in therapeutic nucleic acid conjugate
JP2022578882A JP2023536685A (en) 2020-09-30 2021-09-30 Angiopoietin-like 3 (ANGPTL3) siRNA and uses thereof
CN202211333934.8A CN116333013A (en) 2020-09-30 2021-09-30 Targeting ligand
EP21874577.6A EP4223875A1 (en) 2020-09-30 2021-09-30 Sirna of angiopoietin-like 3 (angptl3) and use thereof
PCT/CN2021/122118 WO2022068923A1 (en) 2020-09-30 2021-09-30 Sirna of angiopoietin-like 3 (angptl3) and use thereof
CN202180022902.3A CN115516092A (en) 2020-09-30 2021-09-30 siRNA of angiopoietin-like 3 (ANGPTL 3) and application thereof
EP23173354.4A EP4331608A1 (en) 2020-09-30 2021-09-30 Target ligand
US18/092,202 US20230257750A1 (en) 2020-09-30 2022-12-30 Sirna of angptl3 and use thereof
JP2023054421A JP2023121159A (en) 2020-09-30 2023-03-29 Targeting ligand
US18/130,418 US20240067971A1 (en) 2020-09-30 2023-04-03 Target Ligand

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110008013.3A CN114716489A (en) 2021-01-05 2021-01-05 Targeting ligand and application thereof in therapeutic nucleic acid conjugate

Publications (1)

Publication Number Publication Date
CN114716489A true CN114716489A (en) 2022-07-08

Family

ID=82234435

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110008013.3A Pending CN114716489A (en) 2020-09-30 2021-01-05 Targeting ligand and application thereof in therapeutic nucleic acid conjugate

Country Status (1)

Country Link
CN (1) CN114716489A (en)

Similar Documents

Publication Publication Date Title
CN109462981B (en) Targeting ligands
CN109069529B (en) Targeting ligands for therapeutic compounds
TWI572716B (en) Mononuclear Nucleic Acid Molecules with Nitrogen-Containing Liposomes
TWI527901B (en) A single stranded nucleic acid molecule used to control gene expression
AU2014219019B2 (en) Short interfering nucleic acid (siNA) molecules containing a 2&#39; internucleoside linkage
KR102639586B1 (en) 5&#39;-cyclo-phosphonate modified nucleotides
KR20180056766A (en) Nucleotide compositions and methods thereof
CN105189751B (en) Bridged bicyclic nucleosides
JP7190794B2 (en) Complex of nucleic acid medicine and hyperbranched lipid
WO2009074076A1 (en) A complex molecule interfering the expression of target genes and its preparing methods
CA3187220A1 (en) Systemic delivery of oligonucleotides
TW202237847A (en) Poly-morpholino oligonucleotide gapmers
CN117858948A (en) Novel therapeutic agent delivery moieties and uses thereof
CN116368146A (en) Novel ligands for asialoglycoprotein receptors
TW202237848A (en) Tau-targeting oligonucleotide gapmers
TW202123973A (en) Conjugate of galnac-oligonucleotide for delivery to liver and manufacturing method thereof
CN114716489A (en) Targeting ligand and application thereof in therapeutic nucleic acid conjugate
CN111615404A (en) Compounds and methods for transmembrane delivery of molecules
CN110603330A (en) Oligonucleotide derivative or salt thereof
US20220112493A1 (en) Phosphonoacetate gapmer oligonucleotides
RU2797833C1 (en) Oligonucleotide compositions and methods related to them
KR20210132681A (en) new phosphoramidite
CA3218815A1 (en) Rnai agents for inhibiting expression of mucin 5ac (muc5ac), compositions thereof, and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230927

Address after: 266041 building 21, academician harbor, 171 Jinshui Road, Licang District, Qingdao City, Shandong Province

Applicant after: Naptide (Qingdao) Biomedical Co.,Ltd.

Address before: 266199 building 21, academician harbor, 171 Jinshui Road, Licang District, Qingdao City, Shandong Province

Applicant before: Napeptide Co.,Ltd.

TA01 Transfer of patent application right